{"gene":"NRG1","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":1992,"finding":"NRG1 (heregulin/NDF) was purified as a 44-45 kDa glycoprotein ligand that specifically induces phosphorylation of p185erbB2/Neu receptor at picomolar concentrations, establishing NRG1 as the activating ligand for the ErbB2 receptor tyrosine kinase.","method":"Protein purification from conditioned medium, Scatchard binding analysis, chemical cross-linking with radiolabeled ligand, immunoprecipitation","journal":"Science / Cell","confidence":"High","confidence_rationale":"Tier 1 — two independent purification/binding studies, direct cross-linking showing NRG1-ErbB2 interaction","pmids":["1350381","1348215"],"is_preprint":false},{"year":1993,"finding":"Glial growth factors (GGF), mitogenic proteins for Schwann cells, are alternatively spliced isoforms of NRG1 and act as ligands for p185erbB2 receptor, with alternative splicing generating membrane-attached, intracellular and secreted signaling proteins.","method":"cDNA cloning, alternative splicing analysis, in situ hybridization, receptor binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — molecular cloning with functional receptor binding validation, foundational isoform discovery","pmids":["8096067"],"is_preprint":false},{"year":1993,"finding":"NDF (NRG1) binds with high affinity (Kd ~10^-9 M) to mammary cells via a complex requiring both ErbB2/Neu and an additional cellular co-receptor; ovarian cells overexpressing Neu did not show covalent cross-linking to NDF and lacked NDF-induced PI3-kinase association, indicating cell-type-specific receptor requirements.","method":"Radiolabeled NDF cross-linking, monoclonal antibody blocking, direct binding analysis, PI3-kinase co-immunoprecipitation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal binding and signaling assays demonstrating receptor complex requirement","pmids":["8096177"],"is_preprint":false},{"year":1994,"finding":"Co-expression of ErbB2 and ErbB3 reconstitutes a high-affinity heregulin (NRG1) binding receptor; ErbB3 alone binds heregulin with lower affinity and shows little tyrosine phosphorylation, whereas the ErbB2/ErbB3 heterodimer generates robust tyrosine phosphorylation signaling. Chemical cross-linking confirmed direct interaction of heregulin with both ErbB2 and ErbB3 in the heterodimer.","method":"Receptor transfection/reconstitution, Scatchard binding analysis, 125I-heregulin cross-linking, immunoprecipitation, tyrosine phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution experiment with direct binding and phosphorylation assays, multiple controls","pmids":["7514177"],"is_preprint":false},{"year":1995,"finding":"HRG (NRG1) beta2 stimulates tyrosine phosphorylation of ErbB2, ErbB3, and ErbB4 in breast cancer cells, induces formation of Shc-Grb2 complexes and receptor-Shc complexes, and stimulates PI3-kinase association with ErbB3, revealing multiple inputs into Ras signaling; ErbB3 associates with PI3-kinase but Grb2 associates with ErbB2 and ErbB4 but not ErbB3, indicating mechanistic differences in Ras coupling among ErbB receptors.","method":"Tyrosine phosphorylation assays, co-immunoprecipitation, PI3-kinase association assays, cell proliferation assays","journal":"Cell growth & differentiation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays mapping distinct signaling connections downstream of NRG1","pmids":["9019162"],"is_preprint":false},{"year":1995,"finding":"NRG1 beta isoforms bind ErbB-3 directly (Kd = 2.2 nM) and exert mitogenic effects on keratinocytes, whereas alpha isoforms bind the same receptor with lower affinity and produce minimal mitogenesis, demonstrating that different NRG1 isoforms elicit distinct growth regulatory effects through differential binding affinity to ErbB-3.","method":"Radioligand binding assays, mitogenesis assays, RT-PCR for receptor expression, keratinocyte culture","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — direct binding quantification combined with functional growth assays across multiple isoforms","pmids":["7731691"],"is_preprint":false},{"year":1995,"finding":"HRG (NRG1) induces HER2-HER3 heterodimerization; ATP-binding-site mutants demonstrate that HER2 transphosphorylates HER3 (but not vice versa), and HRG-induced HER3 transphosphorylation enhances SHC and PI3-kinase association and confers transforming activity to NIH 3T3 cells co-expressing HER2 and HER3.","method":"ATP-binding-site kinase-dead mutants, co-immunoprecipitation, NIH 3T3 transformation assay, PI3-kinase association assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — kinase-dead mutagenesis establishing directionality of transphosphorylation, transformation assay validating oncogenic mechanism","pmids":["7556068"],"is_preprint":false},{"year":1996,"finding":"ErbB-2 functions as a pan-ErbB auxiliary subunit by forming heterodimers with both ErbB-1 (EGFR) and NDF receptors (ErbB-3 and ErbB-4); ErbB-2 overexpression enhances binding affinities of both EGF and NDF by decelerating ligand dissociation rates, thereby prolonging and potentiating downstream ERK and SAPK/JNK signaling cascades. Removal of ErbB-2 from the cell surface almost completely abolished NDF binding.","method":"ErbB-2 overexpression, ER-trapped antibody to block cell surface delivery, kinetic binding analysis, co-immunoprecipitation, MAP kinase/JNK activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function ErbB-2 manipulation with quantitative kinetic binding measurements and downstream signaling readouts","pmids":["8617201"],"is_preprint":false},{"year":1996,"finding":"GGF/neuregulin (NRG1) acts as a mitogen for pro-oligodendrocytes and oligodendrocytes, promotes their survival under serum-free conditions, and at high concentrations reversibly inhibits differentiation and lineage commitment; all three ErbB receptors (ErbB2, ErbB3, ErbB4) are expressed by oligodendrocyte progenitors and are activated by GGF, with relative abundance changing during differentiation. Cortical neurons release a soluble GGF-like mitogen for pro-oligodendrocytes that is blocked by anti-GGF antibodies.","method":"Cell culture proliferation/survival assays, antibody blocking, Western blot for ErbB receptor phosphorylation, neuron-conditioned medium experiments","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with receptor activation analysis and antibody blocking controls","pmids":["8780647"],"is_preprint":false},{"year":1996,"finding":"GGF/neuregulin (NRG1) is expressed by migrating cortical neurons and promotes their migration along radial glial fibers; concurrently, GGF promotes maintenance and elongation of radial glial cells via ErbB2 receptor signaling. In the absence of ErbB2-mediated GGF signaling, radial glial development is abnormal. GGF regulation of radial glial development is mediated in part by brain lipid-binding protein (BLBP).","method":"In vivo mouse cortical development analysis, antibody inhibition, ErbB2 knockout analysis, BLBP expression studies","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic and antibody-blocking experiments with defined cellular phenotypes","pmids":["9342043"],"is_preprint":false},{"year":1997,"finding":"NRG1 isoform-specific functions in vivo: Type I neuregulin is required for generation of neural crest-derived neurons in cranial ganglia and for trabeculation of the heart ventricle, while Type III neuregulin plays an important role in early Schwann cell development, demonstrating that distinct NRG1 isoforms have non-redundant functions in development.","method":"Targeted isoform-specific gene mutations in mice, in situ hybridization, histological analysis of developmental phenotypes","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — isoform-specific knockout mice with distinct developmental phenotypes, replicated across multiple tissue systems","pmids":["9342050"],"is_preprint":false},{"year":1997,"finding":"NDF (NRG1) signaling in prostate cancer cells via ErbB3/ErbB2 heterodimers (not ErbB1) activates PI3-K, ERK/MAPK, mHOG/p38, and JNK/SAPK pathways but not PLCγ or STAT signaling; ErbB3-PI3-K association forms a striking 'activation complex' with multiple tyrosine-phosphorylated species. NDF inhibits LNCaP growth and induces epithelial-like morphological change in contrast to TGF-α.","method":"Immunoprecipitation, Western blot for phosphorylation, PI3-K activation assays, proliferation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — comprehensive signaling pathway mapping in a single cell line with biochemical assays","pmids":["9400997"],"is_preprint":false},{"year":1997,"finding":"Schwann cells express NDF and SMDF/n-ARIA NRG1 mRNAs, secrete neuregulin protein (~45 kDa), and show constitutive activation of ErbB3 receptor, demonstrating an autocrine neuregulin loop in Schwann cells. An anti-neuregulin antibody inhibits Schwann cell proliferation in response to neurons and also blocks proliferation induced by unrelated mitogens including bFGF, HGF, and TGF-β1, indicating that neuregulin autocrine signaling is a convergence point for multiple mitogenic signals.","method":"RT-PCR, ELISA for neuregulin secretion, ErbB3 activation assays, antibody blocking of proliferation","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 — direct secretion measurement and antibody blocking establishing autocrine loop with functional consequence","pmids":["9417836"],"is_preprint":false},{"year":1997,"finding":"Neuregulin-2 (NRG-2) is a distinct gene product (not NRG1) whose EGF-like domain binds ErbB3 and ErbB4; however, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles than NRG1, indicating that NRG1 and NRG-2 mediate distinct biological processes despite shared receptor binding.","method":"Ligand binding assays, receptor phosphorylation profiling, expression analysis","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 — comparative binding and phosphorylation analysis distinguishing NRG1 from NRG2","pmids":["9168115"],"is_preprint":false},{"year":1998,"finding":"NRG1 (as rhGGF2) promotes survival, inhibits apoptosis, and induces hypertrophic growth of neonatal and adult rat cardiac myocytes via ErbB2 and ErbB4 receptors expressed on these cells. NRG1 mRNA is produced by coronary microvascular endothelial cells and is upregulated by endothelin-1, establishing a paracrine endothelial-to-cardiomyocyte NRG1 signaling axis.","method":"Isolated cardiomyocyte cultures, proliferation/apoptosis assays, receptor phosphorylation, RT-PCR for NRG1 in endothelial cells, endothelin-1 stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays (proliferation, survival, hypertrophy) in primary cardiomyocytes with receptor identification","pmids":["9553078"],"is_preprint":false},{"year":1999,"finding":"MPA (progestin) induces HRG (NRG1) mRNA expression in mouse mammary tumor cells; antisense oligonucleotides to HRG inhibit MPA-induced cell growth, demonstrating HRG acts as a mediator of progestin-induced proliferation. Both HRG and MPA proliferative effects require ErbB-2 and a functional IGF-1 receptor.","method":"Antisense oligodeoxynucleotides, RT-PCR, tyrosine phosphorylation assays, proliferation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 — antisense knockdown with proliferation readout, single lab study","pmids":["10597237"],"is_preprint":false},{"year":1999,"finding":"In human ovarian carcinoma cells, NRG1 (HRG) activates HER3 independently of HER2 in some cell lines; EGF preferentially induces EGFR-HER2 heterodimers while HRG preferentially activates HER3/HER4 depending on receptor abundance; EGF and HRG mediate cell growth through distinct receptor complexes (EGFR/HER2 vs. HER4), while HER3 alone does not mediate growth even when phosphorylated.","method":"Receptor co-immunoprecipitation, phosphorylation assays, proliferation assays across cell lines with different receptor expression","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — comparative analysis across multiple cell lines with distinct receptor compositions","pmids":["10733345"],"is_preprint":false},{"year":2002,"finding":"NRG1 was identified as a susceptibility gene for schizophrenia by genome-wide linkage scan and haplotype-association analysis; NRG1 hypomorphic mice have fewer functional NMDA receptors, and ErbB4 receptor reduction produces behavioral phenotypes overlapping with mouse models of schizophrenia. The behavioral phenotypes of NRG1 hypomorphs are partially reversible with clozapine treatment.","method":"Genome-wide linkage scan, haplotype association, NRG1 hypomorph mouse behavioral analysis, NMDA receptor quantification, clozapine pharmacological rescue","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic hypomorph mouse model with NMDA receptor quantification and pharmacological rescue","pmids":["12145742","12478479"],"is_preprint":false},{"year":2003,"finding":"In differentiated human airway epithelia, NRG1 (heregulin-alpha) is segregated exclusively to the apical membrane while its receptors ErbB2-4 localize to the basolateral membrane, physically separated by tight junctions. Upon mechanical injury, heregulin-alpha activates ErbB2 in cells at the wound edge, promoting restoration of epithelial integrity. This ligand-receptor segregation mechanism regulates NRG1/ErbB signaling.","method":"Confocal microscopy of polarized epithelia, mechanical injury assays, receptor phosphorylation after injury, tight junction manipulation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — direct localization imaging with functional wound-healing consequence, strong mechanistic link","pmids":["12646923"],"is_preprint":false},{"year":2005,"finding":"αvβ3 integrin regulates NRG1 (HRG)-induced ERK1/2 MAPK activation and cell proliferation; HRG promotes αvβ3 expression through its downstream effector CYR61; blockade of αvβ3 impairs HRG-promoted ERK1/2 hyperactivation without altering AKT activation, and αvβ3 antagonists decrease S- and G2/M-phase subpopulations with increased p27Kip1 nuclear translocation.","method":"αvβ3 antagonists, antisense oligodeoxynucleotides, flow cytometry, ERK/AKT phosphorylation assays, p27Kip1 nuclear translocation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 — multiple pharmacological and antisense tools but single lab","pmids":["15782133"],"is_preprint":false},{"year":2006,"finding":"In schizophrenia postmortem prefrontal cortex, NRG1-induced activation of ErbB4 is markedly increased compared to controls despite no change in NRG1 or ErbB4 protein levels. This hyperactivation correlates with substantially increased ErbB4-PSD95 interactions (PSD95 facilitates ErbB4 activation). NRG1 stimulation suppresses NMDA receptor activation in human prefrontal cortex, and this suppression is more pronounced in schizophrenia, suggesting NRG1-ErbB4 hyperactivation contributes to NMDA receptor hypofunction.","method":"Postmortem tissue stimulation with NRG1, ErbB4 phosphorylation assays, PSD95-ErbB4 co-immunoprecipitation, NMDA receptor activation measurement","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — novel postmortem tissue stimulation approach with co-IP and functional NMDA receptor readout in human tissue","pmids":["16767099"],"is_preprint":false},{"year":2006,"finding":"Disease-associated SNPs in the 5' upstream region of NRG1 regulate mRNA expression of specific isoforms: SNP8NRG221132 interacts with schizophrenia diagnosis to affect Type I NRG1 (34% increase in schizophrenia), and SNP8NRG243177 within the risk haplotype is associated with expression of the novel Type IV NRG1 isoform. Bioinformatic analysis reveals these SNPs alter binding sites for SRF, MYT1, and HMG Box Protein-1 transcription factors.","method":"Quantitative RT-PCR of postmortem hippocampus, genotype-expression correlation, bioinformatic promoter analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 — expression-genotype correlation in postmortem tissue with bioinformatic analysis of TF binding","pmids":["16618933"],"is_preprint":false},{"year":2007,"finding":"Notch1 signaling in ventricular endocardium directly regulates EphrinB2 expression (a direct Notch transcriptional target), which acts upstream of NRG1 in trabeculation; NRG1 signaling mediates cardiomyocyte differentiation downstream of Notch-EphrinB2, while BMP10 independently regulates cardiomyocyte proliferation. RBPJk/Notch1 mutants show attenuated NRG1 expression and signaling.","method":"RBPJk and Notch1 mutant mice, NRG1 expression analysis, exogenous NRG1 rescue of differentiation defects in cultured RBPJk mutant hearts, luciferase reporter assays for EphrinB2 as Notch target","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with rescue experiments placing NRG1 downstream of Notch-EphrinB2 in cardiac trabeculation","pmids":["17336907"],"is_preprint":false},{"year":2009,"finding":"NRG1 induces mononucleated (but not binucleated) cardiomyocytes to proliferate via ErbB4 signaling; genetic inactivation of ErbB4 reduces cardiomyocyte proliferation while increased ErbB4 expression enhances it. Injection of NRG1 in adult mice induces cardiomyocyte cell-cycle activity and promotes myocardial regeneration, improving cardiac function after myocardial infarction without contribution from undifferentiated progenitor cells.","method":"ErbB4 genetic knockout/overexpression, NRG1 injection in adult mice, cardiomyocyte cell cycle analysis, post-infarction cardiac function measurement, cell lineage tracing","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function genetic models with in vivo functional readouts and lineage tracing","pmids":["19632177"],"is_preprint":false},{"year":2009,"finding":"NRG1/ERBB3 signaling inhibits melanocyte maturation and promotes undifferentiated, migratory, and proliferative characteristics; ERBB3 signaling was necessary and sufficient to inhibit differentiation of later-stage melanocytes in culture. NRG1-treated melanocytes showed increased proliferation, invasion, and altered morphology with decreased differentiation gene expression and increased proliferation/metastasis gene levels.","method":"ERBB3 knockout analysis in embryos, NRG1 treatment of cultured melanocytes, proliferation/invasion assays, gene expression profiling","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic analysis combined with in vitro NRG1 treatment with multiple functional readouts","pmids":["19659570"],"is_preprint":false},{"year":2009,"finding":"Erbin, a protein with LRR and PDZ domains that interacts specifically with ErbB2, is necessary for NRG1 signaling and myelination of the peripheral nervous system. Erbin null mice show hypomyelination and aberrant unmyelinated axon ensheathing; Erbin's PDZ domain binds and stabilizes ErbB2, which is required for NRG1 signaling. Loss of Erbin destabilizes ErbB2 protein and compromises NRG1 signaling.","method":"Erbin knockout and PDZ-domain-deleted knockin mice, sciatic nerve histology, ErbB2 protein stability assays, nerve conduction velocity measurement, siRNA knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic mouse models with molecular mechanism (PDZ-ErbB2 stabilization) and physiological readouts","pmids":["19458253"],"is_preprint":false},{"year":2010,"finding":"LH induces expression of Type III NRG1 transcripts in granulosa cells in an ERK1/2 and C/EBPβ-dependent manner during ovulation. NRG1 binds ERBB3/ERBB2 complexes on granulosa and cumulus cells, selectively stimulates AKT/PKB phosphorylation over ERK1/2, and synergizes with amphiregulin (AREG) to enhance ERK1/2 phosphorylation, progesterone production, and oocyte developmental competence.","method":"Western blotting, granulosa cell culture, AKT/ERK phosphorylation assays, progesterone RIA, oocyte developmental competence assay, conditional ERK1/2 inhibition","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — defined signaling pathways with multiple functional readouts in physiological ovulatory model","pmids":["21047912"],"is_preprint":false},{"year":2011,"finding":"NRG1 isoform expression in the brain is regulated by neuronal activity; activity causes significant increases in Type I and Type IV NRG1. Type IV NRG1 upregulation by neuronal activity requires a CRE cis-element in the 5' UTR that binds CREB transcription factor. Each NRG1 isoform (Types I-VI) shows a distinct developmental expression pattern and is regulated by distinct mechanisms.","method":"RT-PCR for isoform quantification, CREB binding site mutation, luciferase reporter assays, neuronal activity manipulation (KCl depolarization)","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — CRE element mutagenesis with reporter assay establishing transcriptional mechanism for activity-dependent Type IV regulation","pmids":["21653853"],"is_preprint":false},{"year":2013,"finding":"RET and NRG1 genetically interact in Hirschsprung disease; in mouse neural crest cells, NRG1 inhibits GDNF-induced neuronal differentiation and GDNF negatively regulates NRG1 signaling by downregulating ErbB2 receptor expression, indicating that the balance between NRG1/ErbB and RET/GDNF signaling is critical for enteric nervous system neurogenesis/gliogenesis.","method":"Mouse neural crest cell culture, NRG1 and GDNF treatment, neuronal differentiation assays, receptor expression analysis by Western blot, conditional logistic regression for genetic interactions","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 3 — functional interaction in cell culture with receptor downregulation mechanism, single lab","pmids":["23400839"],"is_preprint":false},{"year":2014,"finding":"p63 transcription factor directly activates NRG1 gene transcription in mammary basal cells during pregnancy; basal cell NRG1 signals paracrinally to luminal cells via ERBB4, leading to STAT5A activation and luminal progenitor cell maturation for lactation. Genetic deletion of p63 exclusively in basal cells causes lactation failure due to failure of luminal cell proliferation and differentiation.","method":"Conditional p63 knockout in adult mammary basal cells, ChIP for p63 binding to Nrg1 promoter, ERBB4/STAT5A phosphorylation assays, mammary gland histology and functional lactation assay","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — ChIP establishes direct transcriptional regulation, conditional KO with defined cellular phenotype, signaling pathway validated","pmids":["24412575"],"is_preprint":false},{"year":2014,"finding":"TrkB interacts with ErbB4 (the NRG1 receptor) and this interaction is increased following NRG1 treatment; NRG1 induces GABAR-mediated TrkB activation and BDNF release via ErbB4, which in turn phosphorylates NMDA receptor subunit NR2B. TrkB kinase inhibition or TrkB siRNA suppresses NRG1-induced NR2B activation, and TrkB-ErbB4 interaction is reduced in prefrontal cortex of schizophrenia subjects.","method":"Co-immunoprecipitation, proximity ligation assay, TrkB inhibitor K252a, TrkB siRNA, TrkB knockout neurons, BDNF neutralizing antibody, TrkB domain mutants","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods (Co-IP, PLA, KO neurons, domain mutants) establishing TrkB-ErbB4 interaction and pathway","pmids":["25052836"],"is_preprint":false},{"year":2014,"finding":"mTORC2 is a necessary component of HRG (NRG1)/ErbB2-induced cellular transformation; HRG activates PI3-kinase and mTORC1, and mTORC2 regulates the AKT/TSC2/mTORC1 axis by controlling AKT phosphorylation at both T308 (PDK1-dependent) and S473 (mTORC2-dependent) sites. Elimination of Rictor (mTORC2 component) abolishes both mTORC1 activation and HRG-mediated anchorage-independent growth.","method":"mTOR inhibitors (rapamycin and INK-128), Rictor siRNA/knockout, AKT phosphorylation assays at multiple sites, anchorage-independent growth assays","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic mTORC2 inhibition with biochemical dissection of AKT phosphorylation sites","pmids":["24615340"],"is_preprint":false},{"year":2015,"finding":"DISC1 inhibits NRG1-induced ErbB4 activation in mature cortical interneurons; this inhibition is mediated by competitive inhibition of ErbB4 binding to PSD95 by DISC1. Cell-type-specific gene modulation shows that interneuronal DISC1 affects NRG1-ErbB4-mediated phenotypes in fast-spiking interneuron-pyramidal neuron circuits.","method":"Cell-type-specific viral gene modulation in vitro and in vivo, mutant DISC1 mouse model, ErbB4 phosphorylation assays, PSD95-ErbB4 co-immunoprecipitation, electrophysiology","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — mechanistic competition for PSD95 binding validated by biochemistry and confirmed in mouse model with electrophysiological readouts","pmids":["26656849"],"is_preprint":false},{"year":2015,"finding":"NRG1 and HGF provide resistance to MEK inhibitor (trametinib) treatment in metastatic uveal melanoma; mechanistically, trametinib enhances NRG1 responsiveness, and NRG1 sustains AKT signaling through ERBB3 to bypass MEK inhibition. Inhibition of ERBB3 or AKT overcomes NRG1-provided resistance; stromal fibroblasts producing NRG1 confer resistance via paracrine signaling.","method":"Growth factor screening, NRG1 stimulation with MEK inhibitor, AKT/ERBB3 phosphorylation assays, ERBB3 inhibition, conditioned medium experiments, xenograft models","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway established with multiple pharmacological tools in vitro and in vivo","pmids":["25952648"],"is_preprint":false},{"year":2016,"finding":"CD74-NRG1 fusion gene expression promotes phosphorylation of ErbB2/3, activates PI3K/AKT/NF-κB signaling, and enhances expression of secreted IGF2 in an NF-κB-dependent manner; IGF2 activates IGF1R to create an autocrine/paracrine circuit that promotes cancer stem cell properties and tumor initiation. Inhibition of ErbB2, PI3K, NF-κB, or IGF2 suppresses tumor sphere formation.","method":"ErbB2/3 phosphorylation assays, NF-κB reporter, IGF2 ELISA, IGF1R phosphorylation, limiting dilution xenograft assay, pharmacological inhibition of pathway components","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic signaling pathway traced through NF-κB to IGF2 autocrine loop with multiple inhibitors and in vivo xenograft validation","pmids":["26837769"],"is_preprint":false},{"year":2016,"finding":"A RET-ER81-NRG1 signaling pathway in mechanosensory neurons is required for Pacinian corpuscle formation; Ret maintains Er81 expression, Er81 (but not myelination-related NRG1 isoforms) controls specific Nrg1 isoform expression needed for axon-nonmyelinating Schwann cell communication. Ablating Nrg1 in mechanosensory neurons eliminates Pacinian corpuscles, and distinct NRG1 isoforms are used to interact with myelinating vs. non-myelinating Schwann cells.","method":"Er81 conditional knockout, Nrg1 conditional knockout in sensory neurons, histological analysis of Pacinian corpuscles, isoform-specific RT-PCR","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — conditional knockout genetics establishing epistatic pathway with isoform-specific molecular mechanism","pmids":["27707970"],"is_preprint":false},{"year":2017,"finding":"Spironolactone inhibits ErbB4 receptor phosphorylation and acts as an antagonist of NRG1-ErbB4 signaling; transgenic mice overexpressing Nrg1 type III display cortical ErbB4 hyperphosphorylation, and spironolactone treatment reverses this hyperphosphorylation. Spironolactone treatment ameliorates schizophrenia-relevant behavioral endophenotypes (sensorimotor gating, hyperactivity, working memory) in Nrg1 type III transgenic mice and increases spontaneous inhibitory postsynaptic currents in cortical slices.","method":"Cell-based split-TEV assay screening, ErbB4 phosphorylation biochemical assays, NRG1 type III transgenic mice, behavioral tests, cortical slice electrophysiology","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological mechanism validated in transgenic mouse model with electrophysiological and behavioral readouts","pmids":["28743784"],"is_preprint":false},{"year":2018,"finding":"NRG1-Fc (a fusion protein of NRG1 EGF-like domain with IgG1 Fc domain) triggers potent AKT activation in the liver, lowers blood glucose, improves insulin sensitivity, and suppresses food intake in obese mice. NRG1-Fc acts as a secretagogue for FGF21 (largely dispensable for its metabolic effects) and directly targets hypothalamic POMC neurons to promote membrane depolarization and increase firing rate, establishing dual hepatic and central mechanisms.","method":"NRG1-Fc injection in obese mice, AKT phosphorylation in liver, electrophysiology of POMC neurons, FGF21 knockout mice, glucose tolerance tests","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — dual central and hepatic mechanisms established with electrophysiology and genetic FGF21 knockout controls","pmids":["29515030"],"is_preprint":false},{"year":2018,"finding":"SLC3A2-NRG1 fusion protein contains the SLC3A2 transmembrane domain and NRG1 EGF-like domain; it binds ERBB3 and ERBB4, promotes ERBB2-ERBB3 heterocomplex formation, and activates PI3K-AKT and MAPK signaling to drive colony formation and tumor growth. Dual inhibition of both ERBB2 and ERBB3 (but not either alone) is required to effectively block downstream signaling from this fusion.","method":"Ligand-receptor binding assays, ERBB2/3 co-immunoprecipitation, siRNA knockdown of ERBB2/ERBB3, pharmacological inhibition (pertuzumab, lumretuzumab, afatinib), xenograft models","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — binding assays confirming receptor engagement, dual knockdown establishing signaling requirement, validated in vivo","pmids":["29959202"],"is_preprint":false},{"year":2019,"finding":"NRG1 fusions (including CD74-NRG1, ATP1B1-NRG1, SDC4-NRG1) encode chimeric ligands that activate ERBB receptor tyrosine kinase family signaling by presenting the NRG1 EGF-like domain on the cell surface, leading to HER3-HER2 heterodimerization and downstream PI3K-AKT and MAPK pathway activation, driving oncogenic growth in solid tumors.","method":"RNA sequencing for fusion detection, ERBB2/3 phosphorylation assays in fusion-positive cell lines, xenograft tumor models, bispecific antibody (zenocutuzumab) blocking of HER3-NRG1 interaction","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 — mechanism validated across multiple fusion partners with in vitro signaling assays and in vivo xenograft models","pmids":["35135829"],"is_preprint":false},{"year":2020,"finding":"NRG1 ubiquitination is increased in stress-susceptible mice; the E3 ubiquitin ligase Nedd4l directly targets NRG1 for ubiquitin-mediated degradation in the medial prefrontal cortex (mPFC). Overexpression of Nedd4l decreases NRG1 protein levels and causes vulnerability to stress-induced depression-like behaviors, while downregulation of Nedd4l in mPFC rescues stress vulnerability. NRG1 overexpression attenuates depression-like behaviors in CSDS model.","method":"Ubiquitination assays, Nedd4l overexpression/knockdown via viral vectors, NRG1 protein quantification, CSDS behavioral model, RNA sequencing","journal":"Translational psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 — E3 ligase-substrate relationship established with ubiquitination assay and bidirectional in vivo manipulation","pmids":["32703967"],"is_preprint":false},{"year":2020,"finding":"NRG1/ERBB4 autocrine signaling in cardiac endothelial cells (ECs) plays a role in modulating hypertrophic and fibrotic responses during early cardiac remodeling; EC-specific ERBB4 knockout attenuates myocardial hypertrophy and fibrosis 8 weeks after transverse aortic constriction and reduces fibrosis after angiotensin II treatment, though these differences normalize over time. RNA sequencing shows NRG1 controls expression of hypertrophic and fibrotic pathway genes in ECs.","method":"EC-specific Erbb4 conditional knockout, transverse aortic constriction model, angiotensin II treatment, cardiac histology, RNA sequencing of cultured ECs","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific knockout with defined cardiac phenotype and transcriptomic mechanism","pmids":["32618511"],"is_preprint":false},{"year":2021,"finding":"Biallelic variants in ERBB3 and ERBB2 (NRG1 receptors) cause a developmental disorder with HSCR, CIPO, peripheral neuropathy, and arthrogryposis; gut histology reveals aganglionosis and smooth muscle abnormalities. Mouse single-cell RNA sequencing and conditional ErbB3-deficient mouse show a primary role for ERBB3 in enteric progenitors. Functional analyses reveal the identified variants cause decreased expression or altered phosphorylation of the mutant receptors.","method":"Trio-exome sequencing, ErbB3 conditional mouse knockout, single-cell RNA sequencing, RT-qPCR and immunoblot of patient-derived fibroblasts and transfected cells","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — human genetics validated by mouse conditional knockout with single-cell transcriptomic characterization","pmids":["33497358"],"is_preprint":false},{"year":2021,"finding":"VAMP2-NRG1 and SLC3A2-NRG1 fusion proteins are membrane-bound and display the NRG1 EGF-like domain extracellularly; KRAS mutation increases ADAM17 metalloprotease activity, which cleaves/sheds NRG1 from the SLC3A2-NRG1 fusion protein via KRAS-MEK-ERK signaling, enhancing ERBB2-ERBB3 phosphorylation and downstream PI3K/AKT/mTOR signaling even under oncogenic KRAS. MEK1/2 and ADAM17 inhibitors synergistically induce apoptosis.","method":"ADAM17 activity assays, MEK inhibitors, NRG1 shedding measurement, ERBB2/3 phosphorylation, xenograft and lung orthotopic tumor models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — ADAM17-mediated NRG1 shedding mechanism established with enzymatic assays and pharmacological inhibition in multiple models","pmids":["34743207"],"is_preprint":false},{"year":2021,"finding":"Stromal cancer-associated fibroblasts (CAFs) express NRG1 and signal paracrinally to luminal breast cancer cells to phosphorylate HER3 (ERBB3) and activate AKT and ERK1/2; simultaneously, NRG1 drives a HER3-independent pro-fibrotic and migratory phenotype in CAFs themselves. HAS2 (Hyaluronan Synthase 2) is identified as a targetable molecule strongly correlated with NRG1 in CAFs.","method":"CAF-conditioned medium, NRG1 neutralizing antibodies, siRNA knockdown, HER3 phosphorylation assays, CAF migration/invasion assays, transcriptomic profiling","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional NRG1 signaling (paracrine to cancer cells, autocrine in CAFs) demonstrated with multiple functional assays","pmids":["33692466"],"is_preprint":false},{"year":2021,"finding":"NRG1/ErbB signaling controls dialogue between foxd3-positive neural crest-derived cells (NCdC) and macrophages during zebrafish fin regeneration; NCdC regulate macrophage recruitment and polarization through the NRG1/ErbB pathway, which is required for blastema formation. Chemical inhibition and transcriptomic analysis establish NRG1/ErbB pathway as the molecular link between NCdC and macrophage behavior during regeneration.","method":"Triple transgenic zebrafish live imaging, genetic NCdC depletion, NRG1/ErbB chemical inhibition, single-cell RNA sequencing, transcriptomic analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological manipulation with scRNA-seq establishing pathway in defined cellular context","pmids":["34732706"],"is_preprint":false},{"year":2021,"finding":"NFKB2 directly binds the promoter region of NRG1 and inhibits NRG1 transcription; in IL-1β-stimulated nucleus pulposus cells, NFKB2 is upregulated leading to NRG1 downregulation. NRG1 activates ErbB2/3 to sustain PI3K-AKT signaling protecting against degenerative changes; NFKB2 silencing attenuates degeneration via NRG1, and this effect is reversed by NRG1 silencing.","method":"ChIP for NFKB2 binding to NRG1 promoter, luciferase reporter assays, siRNA knockdown, ErbB2/3 and AKT phosphorylation assays, cell viability and apoptosis assays","journal":"Mechanisms of ageing and development","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay establish direct transcriptional repression, validated by epistasis with NRG1 knockdown","pmids":["34023356"],"is_preprint":false},{"year":2023,"finding":"Nrg1 regulates cardiomyocyte-oriented cell division and trabeculae formation through endocardial Nrg1-to-myocardial ErbB2 signaling and phospho-ERK activation; early loss of Nrg1 reduces cardiomyocyte Pard3 and Crumbs2 polarity proteins, alters cytoskeletal actin gene expression, and shifts cardiomyocyte division orientation. Nrg1 is required for an EMT-like process in cardiomyocytes including migration, adhesion, and G2/M cell cycle progression. Ectopic Nrg1 overexpression causes S-phase arrest and prolonged trabeculation. Yap1 nuclear-cytoplasmic distribution is influenced by Nrg1 via pERK.","method":"Cardiac-specific Nrg1 knockout and overexpression, confocal imaging, transcriptomics, pERK and Pard3/Crumbs2 protein analysis, cell division orientation measurement, Yap1 nuclear-cytoplasmic localization imaging","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (KO and OE) with multiple orthogonal biochemical and imaging readouts establishing Nrg1-ErbB2-pErk-Yap1 axis","pmids":["37846569"],"is_preprint":false},{"year":2023,"finding":"In pancreatic ductal adenocarcinoma, cancer-associated fibroblasts (CAFs) secrete NRG1 which activates ERBB2 and ERBB3 on cancer cells as a KRAS*-independent survival mechanism. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 expression in cancer cells, prompting utilization of CAF-derived NRG1. Genetic depletion or pharmacological inhibition of ERBB2/3 or NRG1 abolishes KRAS bypass and synergizes with KRASG12D inhibitors.","method":"KRAS* conditional extinction, NRG1 genetic depletion in CAFs, ERBB2/3 pharmacological inhibition, KRASG12D inhibitor combination in mouse and human PDAC models","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — causal genetic and pharmacological manipulation in multiple models establishing CAF-NRG1-ERBB2/3 as resistance mechanism","pmids":["37775182"],"is_preprint":false},{"year":2023,"finding":"NRG1 fusions activate downstream signaling not only through HER2-HER3 heterodimers but also through HER4 independently of other HER family members, and through EGFR-HER3 signaling. Inhibition of HER4 and EGFR in addition to HER2/HER3 is necessary to effectively inhibit NRG1 fusion-driven tumor cell growth; pan-HER inhibition is more effective than selective targeting of HER2-HER3 or HER3 alone.","method":"Ba/F3 engineered cell lines with defined HER family member combinations, ERBB phosphorylation assays, cetuximab/trastuzumab/pertuzumab combination studies, in vitro and in vivo tumor growth assays with pan-HER TKIs","journal":"Journal of thoracic oncology","confidence":"Medium","confidence_rationale":"Tier 2 — engineered cell systems with defined receptor compositions establishing HER4/EGFR contributions, validated in vivo","pmids":["37678511"],"is_preprint":false},{"year":2024,"finding":"Adipocyte precursors secrete NRG1 which activates ERBB3 (HER3) signaling on urothelial and lung cancer cells in a paracrine manner, conferring resistance to FGFR inhibition (erdafitinib). NRG1 expression is significantly higher in adipocyte precursors than terminally differentiated adipocytes. NRG1 knockdown in adipocyte precursors abrogates resistance; pharmacological inhibition of the NRG1/HER3 axis with pertuzumab reverses erdafitinib resistance in vivo.","method":"Co-culture of adipocyte precursors and cancer cells, NRG1 knockdown in adipocyte precursors, ERBB3 phosphorylation assays, pertuzumab treatment, xenograft survival experiments, scRNA-seq","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — paracrine mechanism with knockdown and antibody blocking, validated in xenograft in vivo","pmids":["38175774"],"is_preprint":false}],"current_model":"NRG1 is a secreted/membrane-anchored EGF-like growth factor that signals primarily by binding ErbB3 (HER3) and ErbB4 (HER4) receptors, which heterodimerize with ErbB2 (HER2) — stabilized by ErbB2 acting as a pan-ErbB auxiliary subunit that decelerates ligand dissociation and amplifies signaling — to activate downstream PI3K-AKT, MAPK/ERK, and SAPK/JNK pathways; NRG1 produces multiple functionally distinct isoforms through alternative promoter usage and splicing (Types I–VI), with isoform-specific roles in Schwann cell myelination (Type III), cranial ganglia and cardiac trabeculation (Type I), and activity-dependent synaptic regulation (Types I/IV), the latter controlled by CREB-dependent transcription; NRG1 protein stability is regulated by the E3 ubiquitin ligase Nedd4l-mediated ubiquitination and degradation, and ErbB2 receptor stability is maintained by the adaptor Erbin via its PDZ domain; NRG1 plays essential roles in cardiac trabeculation (endocardial-to-myocardial paracrine signaling through ErbB2-pERK-Yap1), cardiomyocyte proliferation and regeneration (via ErbB4, selectively in mononucleated cells), oligodendrocyte proliferation/survival, peripheral myelination, mammary lactation (basal-cell p63-driven transcription of NRG1 activating luminal ERBB4/STAT5A), hypothalamic POMC neuron depolarization, and modulation of NMDA receptor function via ErbB4-PSD95 interactions in cortical interneurons; oncogenic NRG1 gene fusions present the EGF-like domain on the cell surface, constitutively activating HER2-HER3 (and HER4/EGFR) heterodimers and downstream PI3K-AKT/MAPK signaling, with CAF-derived paracrine NRG1 also serving as a resistance mechanism to targeted therapies including KRAS and FGFR inhibitors."},"narrative":{"teleology":[{"year":1992,"claim":"Identification of NRG1 as the activating ligand of the ErbB2 receptor tyrosine kinase resolved the long-standing question of what physiological signal triggers p185erbB2 phosphorylation.","evidence":"Protein purification from conditioned medium with Scatchard binding and chemical cross-linking in two independent studies","pmids":["1350381","1348215"],"confidence":"High","gaps":["Direct receptor (ErbB3/ErbB4) had not yet been identified as the primary binding partner","Downstream signaling pathways not yet mapped"]},{"year":1994,"claim":"Reconstitution of the ErbB2–ErbB3 heterodimer as the high-affinity NRG1 receptor established that ErbB2 is not the direct ligand-binding subunit but rather a co-receptor that amplifies signaling through transphosphorylation, while isoform diversity (GGF/heregulin/SMDF) was shown to arise from alternative splicing of a single gene.","evidence":"ErbB2/ErbB3 co-transfection with Scatchard analysis, cross-linking, kinase-dead mutagenesis establishing transphosphorylation directionality; cDNA cloning of GGF isoforms","pmids":["7514177","8096067","7556068"],"confidence":"High","gaps":["Relative contributions of ErbB4 vs ErbB3 in different tissues unclear","Structural basis of heterodimer formation unknown"]},{"year":1996,"claim":"Demonstration that ErbB2 functions as a pan-ErbB auxiliary subunit by decelerating ligand dissociation—and that NRG1 drives oligodendrocyte proliferation/survival and radial glial maintenance—broadened NRG1's role from a receptor activator to a pleiotropic neural growth factor.","evidence":"ErbB2 overexpression/surface-depletion with kinetic binding analysis; oligodendrocyte culture with antibody blocking and ErbB receptor phosphorylation; ErbB2 knockout and cortical development analysis in mice","pmids":["8617201","8780647","9342043"],"confidence":"High","gaps":["Mechanism by which NRG1 controls radial glial vs neuronal targets not separated at isoform level","In vivo relevance of ErbB2 kinetic modulation not yet demonstrated genetically"]},{"year":1997,"claim":"Isoform-specific gene targeting revealed that Type I and Type III NRG1 have non-redundant functions—Type I in cranial ganglia and cardiac trabeculation, Type III in Schwann cell development—demonstrating that alternative splicing generates functionally distinct signaling molecules.","evidence":"Targeted isoform-specific mutations in mice with histological analysis of distinct developmental phenotypes","pmids":["9342050"],"confidence":"High","gaps":["Type IV, V, VI isoform functions not yet characterized","Molecular basis for isoform-specific receptor engagement unknown"]},{"year":2002,"claim":"Linkage and association studies identified NRG1 as a schizophrenia susceptibility locus, and NRG1 hypomorphic mice showed reduced NMDA receptors and clozapine-reversible behavioral phenotypes, connecting NRG1 to synaptic glutamate signaling.","evidence":"Genome-wide linkage scan, haplotype association, NRG1 hypomorph mice with NMDA receptor quantification and pharmacological rescue","pmids":["12145742","12478479"],"confidence":"High","gaps":["Causal variants within the NRG1 locus not identified","Whether NRG1-ErbB4 directly regulates NMDA receptor trafficking or function was unresolved"]},{"year":2006,"claim":"Postmortem studies established that NRG1-induced ErbB4 hyperactivation and enhanced ErbB4–PSD95 interaction suppress NMDA receptor activation in schizophrenia prefrontal cortex, providing a molecular mechanism for NMDA hypofunction; disease-associated SNPs were shown to regulate isoform-specific expression including the novel Type IV isoform.","evidence":"Postmortem tissue NRG1 stimulation with ErbB4 phosphorylation and PSD95 co-IP; quantitative RT-PCR genotype-expression correlation in hippocampus","pmids":["16767099","16618933"],"confidence":"High","gaps":["Whether PSD95–ErbB4 interaction is the primary mechanism of NRG1-induced NMDA suppression in vivo","Functional validation of SNP-altered transcription factor binding sites lacking"]},{"year":2009,"claim":"NRG1–ErbB4 signaling was shown to drive mononucleated cardiomyocyte proliferation and promote myocardial regeneration after infarction, while Erbin was identified as a PDZ-domain adaptor required for ErbB2 stability and NRG1-dependent peripheral myelination.","evidence":"ErbB4 genetic knockout/overexpression with NRG1 injection and lineage tracing in adult mice; Erbin knockout and PDZ-deleted knockin mice with nerve histology and ErbB2 stability assays","pmids":["19632177","19458253"],"confidence":"High","gaps":["Why only mononucleated cardiomyocytes respond to NRG1 is mechanistically unexplained","Whether Erbin functions similarly in CNS myelination unknown"]},{"year":2014,"claim":"Direct transcriptional activation of NRG1 by p63 in mammary basal cells established a basal-to-luminal paracrine axis (NRG1→ERBB4→STAT5A) essential for lactation, revealing cell-type-specific transcriptional control of NRG1 with defined physiological consequences.","evidence":"Conditional p63 knockout in adult mammary basal cells, ChIP for p63 at Nrg1 promoter, ERBB4/STAT5A phosphorylation, functional lactation assay","pmids":["24412575"],"confidence":"High","gaps":["Whether other NRG1 isoforms contribute to mammary development not assessed","Mechanism of STAT5A activation by ERBB4 in this context not fully dissected"]},{"year":2019,"claim":"Characterization of NRG1 gene fusions (CD74-, SLC3A2-, ATP1B1-NRG1) revealed that chimeric proteins constitutively present the EGF-like domain on the cell surface to activate HER2–HER3 heterodimers and PI3K-AKT/MAPK signaling; ADAM17-mediated shedding of fusion NRG1 was later shown to be enhanced by KRAS-MEK-ERK signaling.","evidence":"RNA sequencing for fusion detection, ERBB2/3 phosphorylation assays, zenocutuzumab blocking, ADAM17 activity assays, xenograft models","pmids":["35135829","29959202","34743207"],"confidence":"High","gaps":["Clinical efficacy of NRG1 fusion-targeted therapies not established","Structural basis for constitutive activation by different fusion partners not resolved"]},{"year":2020,"claim":"NRG1 protein stability was shown to be regulated by Nedd4l-mediated ubiquitination in the prefrontal cortex, linking NRG1 degradation to stress vulnerability and depression-like phenotypes and revealing a post-translational control mechanism.","evidence":"Ubiquitination assays, Nedd4l overexpression/knockdown via viral vectors, CSDS behavioral model","pmids":["32703967"],"confidence":"Medium","gaps":["Whether Nedd4l targets specific NRG1 isoforms is unknown","Ubiquitination sites on NRG1 not mapped","Independent replication in a second behavioral paradigm lacking"]},{"year":2023,"claim":"CAF-secreted NRG1 was identified as a KRAS*-independent survival mechanism in pancreatic cancer: KRAS extinction upregulates ERBB2/3 expression, enabling NRG1-driven bypass; paracrine NRG1 from adipocyte precursors similarly confers resistance to FGFR inhibitors, establishing NRG1–ERBB3 as a general therapeutic resistance axis.","evidence":"KRAS conditional extinction with NRG1 genetic depletion in CAFs, ERBB2/3 inhibition in PDAC models; co-culture with adipocyte precursors, NRG1 knockdown, pertuzumab reversal in xenografts","pmids":["37775182","38175774"],"confidence":"High","gaps":["Whether NRG1-mediated resistance generalizes across all KRAS-mutant cancers untested","Direct clinical validation of combination strategies pending"]},{"year":2023,"claim":"An endocardial NRG1–myocardial ErbB2–pERK–Yap1 axis was shown to orient cardiomyocyte cell division and regulate polarity proteins (Pard3, Crumbs2) during trabeculation, unifying earlier genetic observations into a coherent morphogenetic signaling cascade.","evidence":"Cardiac-specific Nrg1 knockout and overexpression with confocal imaging of division orientation, pERK and polarity protein analysis, Yap1 localization","pmids":["37846569"],"confidence":"High","gaps":["How pERK regulates Yap1 nuclear-cytoplasmic distribution mechanistically unresolved","Whether Pard3/Crumbs2 are direct or indirect pERK targets unknown"]},{"year":null,"claim":"Key unresolved questions include the structural basis for isoform-specific receptor selectivity, the full spectrum of NRG1 isoform functions in the adult brain, and the clinical impact of targeting the NRG1–ERBB axis in NRG1 fusion-driven cancers and therapy resistance settings.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of NRG1 isoform-specific receptor complexes","Type V and VI isoform functions remain uncharacterized","Clinical trial results for NRG1 fusion-targeted therapies not yet in primary literature"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,3,5,38,39]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,20,32]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,18,38,43]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,14,44,48,50]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9,10,22,47]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[8,17,20,32]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[34,38,39,48,49]}],"complexes":[],"partners":["ERBB2","ERBB3","ERBB4","PSD95","NEDD4L","ERBIN","ADAM17"],"other_free_text":[]},"mechanistic_narrative":"NRG1 encodes a family of alternatively spliced EGF-like growth factors that signal primarily through ErbB3 (HER3) and ErbB4 (HER4) receptors, which heterodimerize with ErbB2 (HER2) to activate PI3K-AKT, MAPK/ERK, and SAPK/JNK cascades, governing cell proliferation, survival, differentiation, and myelination across neural, cardiac, epithelial, and metabolic tissues [PMID:1350381, PMID:7514177, PMID:8617201, PMID:9019162]. Distinct NRG1 isoforms (Types I–VI) generated by alternative promoter usage and splicing serve non-redundant developmental functions: Type III NRG1 drives Schwann cell development and peripheral myelination, Type I is required for cranial ganglia formation and cardiac trabeculation—where endocardial NRG1 activates myocardial ErbB2–pERK–Yap1 signaling to orient cardiomyocyte division—and activity-dependent Type I/IV expression is controlled by CREB-dependent transcription in neurons [PMID:9342050, PMID:37846569, PMID:21653853]. NRG1–ErbB4 signaling modulates NMDA receptor function via ErbB4–PSD95 interactions in cortical interneurons, and NRG1 hypomorphic mice exhibit reduced NMDA receptors and schizophrenia-relevant behavioral phenotypes partially reversible by clozapine, establishing NRG1 as a schizophrenia susceptibility gene [PMID:12145742, PMID:16767099]. Oncogenic NRG1 gene fusions constitutively present the EGF-like domain at the cell surface to activate HER2–HER3 (and HER4/EGFR) heterodimers, while cancer-associated fibroblast-derived paracrine NRG1 confers resistance to KRAS, MEK, and FGFR inhibitors through sustained ERBB3–AKT signaling [PMID:35135829, PMID:37775182, PMID:38175774]."},"prefetch_data":{"uniprot":{"accession":"Q02297","full_name":"Pro-neuregulin-1, membrane-bound isoform","aliases":[],"length_aa":640,"mass_kda":70.4,"function":"Direct ligand for ERBB3 and ERBB4 tyrosine kinase receptors. Concomitantly recruits ERBB1 and ERBB2 coreceptors, resulting in ligand-stimulated tyrosine phosphorylation and activation of the ERBB receptors. The multiple isoforms perform diverse functions such as inducing growth and differentiation of epithelial, glial, neuronal, and skeletal muscle cells; inducing expression of acetylcholine receptor in synaptic vesicles during the formation of the neuromuscular junction; stimulating lobuloalveolar budding and milk production in the mammary gland and inducing differentiation of mammary tumor cells; stimulating Schwann cell proliferation; implication in the development of the myocardium such as trabeculation of the developing heart. Isoform 10 may play a role in motor and sensory neuron development. Binds to ERBB4 (PubMed:10867024, PubMed:7902537). Binds to ERBB3 (PubMed:20682778). Acts as a ligand for integrins and binds (via EGF domain) to integrins ITGAV:ITGB3 or ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and ERRB3 are essential for NRG1-ERBB signaling. Induces the phosphorylation and activation of MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:20682778). Ligand-dependent ERBB4 endocytosis is essential for the NRG1-mediated activation of these kinases in neurons (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q02297/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NRG1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NRG1","total_profiled":1310},"omim":[{"mim_id":"619465","title":"VISCERAL NEUROPATHY, FAMILIAL, 2, AUTOSOMAL RECESSIVE; VSCN2","url":"https://www.omim.org/entry/619465"},{"mim_id":"615515","title":"AMYOTROPHIC LATERAL SCLEROSIS 19; ALS19","url":"https://www.omim.org/entry/615515"},{"mim_id":"611945","title":"SPASTIC PARAPLEGIA 37, AUTOSOMAL DOMINANT; SPG37","url":"https://www.omim.org/entry/611945"},{"mim_id":"610894","title":"NEUREGULIN 4; NRG4","url":"https://www.omim.org/entry/610894"},{"mim_id":"608984","title":"ATAXIA, SENSORY, 1, AUTOSOMAL DOMINANT; SNAX1","url":"https://www.omim.org/entry/608984"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":15.9}],"url":"https://www.proteinatlas.org/search/NRG1"},"hgnc":{"alias_symbol":["HRG","NDF","GGF"],"prev_symbol":["HGL","NRG1-IT2"]},"alphafold":{"accession":"Q02297","domains":[{"cath_id":"2.60.40.10","chopping":"40-131","consensus_level":"high","plddt":91.7151,"start":40,"end":131},{"cath_id":"2.10.25.10","chopping":"180-228","consensus_level":"high","plddt":80.6014,"start":180,"end":228},{"cath_id":"1.20.5","chopping":"230-287","consensus_level":"medium","plddt":87.8026,"start":230,"end":287}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02297","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q02297-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q02297-F1-predicted_aligned_error_v6.png","plddt_mean":56.66},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NRG1","jax_strain_url":"https://www.jax.org/strain/search?query=NRG1"},"sequence":{"accession":"Q02297","fasta_url":"https://rest.uniprot.org/uniprotkb/Q02297.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q02297/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q02297"}},"corpus_meta":[{"pmid":"8617201","id":"PMC_8617201","title":"ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8617201","citation_count":561,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8780647","id":"PMC_8780647","title":"GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors.","date":"1996","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/8780647","citation_count":321,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9342043","id":"PMC_9342043","title":"Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9342043","citation_count":286,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8096177","id":"PMC_8096177","title":"Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8096177","citation_count":229,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31311833","id":"PMC_31311833","title":"A Coevolved EDS1-SAG101-NRG1 Module Mediates Cell Death Signaling by TIR-Domain Immune Receptors.","date":"2019","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/31311833","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20832498","id":"PMC_20832498","title":"Nrg1/ErbB signaling networks in Schwann cell development and myelination.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20832498","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30582759","id":"PMC_30582759","title":"Diverse NLR immune receptors activate defence via the RPW8-NLR NRG1.","date":"2019","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/30582759","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30988082","id":"PMC_30988082","title":"Detection of NRG1 Gene Fusions in Solid Tumors.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30988082","citation_count":180,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16520822","id":"PMC_16520822","title":"Association of the NRG1 gene and schizophrenia: a meta-analysis.","date":"2006","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16520822","citation_count":173,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35135829","id":"PMC_35135829","title":"Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.","date":"2022","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35135829","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25531467","id":"PMC_25531467","title":"Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25531467","citation_count":137,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21653853","id":"PMC_21653853","title":"Specific regulation of NRG1 isoform expression by neuronal activity.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21653853","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34099661","id":"PMC_34099661","title":"Pathogen effector recognition-dependent association of NRG1 with EDS1 and SAG101 in TNL receptor immunity.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34099661","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31068372","id":"PMC_31068372","title":"NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31068372","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9400997","id":"PMC_9400997","title":"ErbB kinases and NDF signaling in human prostate cancer cells.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9400997","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32916265","id":"PMC_32916265","title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.","date":"2020","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32916265","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8625831","id":"PMC_8625831","title":"Effects of GGF/neuregulins on neuronal survival and neurite outgrowth correlate with erbB2/neu expression in developing rat retina.","date":"1996","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/8625831","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24412575","id":"PMC_24412575","title":"Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.","date":"2014","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/24412575","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15782133","id":"PMC_15782133","title":"AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15782133","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15869579","id":"PMC_15869579","title":"Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG).","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/15869579","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7731691","id":"PMC_7731691","title":"ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731691","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25501131","id":"PMC_25501131","title":"Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25501131","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39908431","id":"PMC_39908431","title":"Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.","date":"2025","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39908431","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22757963","id":"PMC_22757963","title":"BRG1 and NRG1 form a novel feedback circuit regulating Candida albicans hypha formation and virulence.","date":"2012","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/22757963","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19659570","id":"PMC_19659570","title":"NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.","date":"2009","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/19659570","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25996292","id":"PMC_25996292","title":"Activation of NRG1-ERBB4 signaling potentiates mesenchymal stem cell-mediated myocardial repairs following myocardial infarction.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25996292","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9417836","id":"PMC_9417836","title":"Schwann cells express NDF and SMDF/n-ARIA mRNAs, secrete neuregulin, and show constitutive activation of erbB3 receptors: evidence for a neuregulin autocrine loop.","date":"1997","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9417836","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19458253","id":"PMC_19458253","title":"Erbin regulates NRG1 signaling and myelination.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19458253","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16019744","id":"PMC_16019744","title":"Composite PHB-GGF conduit for long nerve gap repair: a long-term evaluation.","date":"2005","source":"Scandinavian journal of plastic and reconstructive surgery and hand surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16019744","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31382039","id":"PMC_31382039","title":"Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.","date":"2019","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31382039","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26656849","id":"PMC_26656849","title":"Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory-inhibitory synapse formation in the mature cortex.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26656849","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28951744","id":"PMC_28951744","title":"IGF1 and NRG1 Enhance Proliferation, Metabolic Maturity, and the Force-Frequency Response in hESC-Derived Engineered Cardiac Tissues.","date":"2017","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/28951744","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25952648","id":"PMC_25952648","title":"Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25952648","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26837769","id":"PMC_26837769","title":"Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26837769","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36261532","id":"PMC_36261532","title":"HRG-9 homologues regulate haem trafficking from haem-enriched compartments.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36261532","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21047912","id":"PMC_21047912","title":"LH-induced neuregulin 1 (NRG1) type III transcripts control granulosa cell differentiation and oocyte maturation.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21047912","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31607147","id":"PMC_31607147","title":"Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.","date":"2019","source":"Circulation. Heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/31607147","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10597237","id":"PMC_10597237","title":"Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597237","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9775980","id":"PMC_9775980","title":"Chronically denervated rat Schwann cells respond to GGF in vitro.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9775980","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32852072","id":"PMC_32852072","title":"Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.","date":"2020","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/32852072","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17300918","id":"PMC_17300918","title":"The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland.","date":"2007","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/17300918","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10733345","id":"PMC_10733345","title":"Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.","date":"1999","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10733345","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23301017","id":"PMC_23301017","title":"Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23301017","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23400839","id":"PMC_23400839","title":"RET and NRG1 interplay in Hirschsprung disease.","date":"2013","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23400839","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38348690","id":"PMC_38348690","title":"The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.","date":"2024","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38348690","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10514432","id":"PMC_10514432","title":"Differential binding of histidine-rich glycoprotein (HRG) to human IgG subclasses and IgG molecules containing kappa and lambda light chains.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10514432","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29515030","id":"PMC_29515030","title":"NRG1-Fc improves metabolic health via dual hepatic and central action.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29515030","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25475805","id":"PMC_25475805","title":"Effects of RET and NRG1 polymorphisms in Indonesian patients with Hirschsprung disease.","date":"2014","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/25475805","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28573357","id":"PMC_28573357","title":"Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.","date":"2017","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/28573357","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28743784","id":"PMC_28743784","title":"Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice.","date":"2017","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28743784","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26134228","id":"PMC_26134228","title":"VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.","date":"2015","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26134228","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37846569","id":"PMC_37846569","title":"Nrg1 Regulates Cardiomyocyte Migration and Cell Cycle in Ventricular Development.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37846569","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32618511","id":"PMC_32618511","title":"The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling.","date":"2020","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32618511","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29959202","id":"PMC_29959202","title":"Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.","date":"2018","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29959202","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33497358","id":"PMC_33497358","title":"Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33497358","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19439994","id":"PMC_19439994","title":"DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study.","date":"2009","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19439994","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32690068","id":"PMC_32690068","title":"CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease.","date":"2020","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32690068","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29225331","id":"PMC_29225331","title":"Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients.","date":"2017","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29225331","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29607874","id":"PMC_29607874","title":"Astraglaus polysaccharide protects diabetic cardiomyopathy by activating NRG1/ErbB pathway.","date":"2018","source":"Bioscience trends","url":"https://pubmed.ncbi.nlm.nih.gov/29607874","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34486669","id":"PMC_34486669","title":"Prrx1b restricts fibrosis and promotes Nrg1-dependent cardiomyocyte proliferation during zebrafish heart regeneration.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34486669","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18704261","id":"PMC_18704261","title":"Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population.","date":"2008","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18704261","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34680187","id":"PMC_34680187","title":"Neuregulin 1 Gene (NRG1). A Potentially New Targetable Alteration for the Treatment of Lung Cancer.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34680187","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24141772","id":"PMC_24141772","title":"HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H(+) ATPase.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141772","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36259930","id":"PMC_36259930","title":"Effector XopQ-induced stromule formation in Nicotiana benthamiana depends on ETI signaling components ADR1 and NRG1.","date":"2023","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36259930","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35370955","id":"PMC_35370955","title":"MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35370955","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27707970","id":"PMC_27707970","title":"A RET-ER81-NRG1 Signaling Pathway Drives the Development of Pacinian Corpuscles.","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27707970","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35876932","id":"PMC_35876932","title":"Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats.","date":"2022","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35876932","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27941874","id":"PMC_27941874","title":"HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27941874","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28857490","id":"PMC_28857490","title":"The acceleration of reproductive aging in Nrg1flox/flox ;Cyp19-Cre female mice.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28857490","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28581477","id":"PMC_28581477","title":"Inter-organ signalling by HRG-7 promotes systemic haem homeostasis.","date":"2017","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28581477","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29121253","id":"PMC_29121253","title":"The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.","date":"2018","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29121253","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9019162","id":"PMC_9019162","title":"Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.","date":"1995","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9019162","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34442867","id":"PMC_34442867","title":"Effects of Age, Diet CP, NDF, EE, and Starch on the Rumen Bacteria Community and Function in Dairy Cattle.","date":"2021","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/34442867","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33413557","id":"PMC_33413557","title":"NRG1 fusions in breast cancer.","date":"2021","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/33413557","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9414276","id":"PMC_9414276","title":"HRG Tokushima: molecular and cellular characterization of histidine-rich glycoprotein (HRG) deficiency.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9414276","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23793459","id":"PMC_23793459","title":"HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via platelet-induced signaling in the pre-tumorigenic microenvironment.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23793459","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32929358","id":"PMC_32929358","title":"HRG switches TNFR1-mediated cell survival to apoptosis in Hepatocellular Carcinoma.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32929358","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37775182","id":"PMC_37775182","title":"Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/37775182","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34743207","id":"PMC_34743207","title":"Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34743207","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34732706","id":"PMC_34732706","title":"NRG1/ErbB signalling controls the dialogue between macrophages and neural crest-derived cells during zebrafish fin regeneration.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34732706","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30662268","id":"PMC_30662268","title":"lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30662268","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33692466","id":"PMC_33692466","title":"Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33692466","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19712047","id":"PMC_19712047","title":"Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19712047","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9621956","id":"PMC_9621956","title":"Predicting forage indigestible NDF from lignin concentration.","date":"1998","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/9621956","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32703967","id":"PMC_32703967","title":"Nedd4l downregulation of NRG1 in the mPFC induces depression-like behaviour in CSDS mice.","date":"2020","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32703967","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32828943","id":"PMC_32828943","title":"Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32828943","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24615340","id":"PMC_24615340","title":"Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24615340","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11057869","id":"PMC_11057869","title":"Histidine-rich glycoprotein (HRG) Tokushima 2: novel HRG deficiency, molecular and cellular characterization.","date":"2000","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11057869","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25052836","id":"PMC_25052836","title":"TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before synaptogenesis.","date":"2014","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/25052836","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21364580","id":"PMC_21364580","title":"Expression of NRG1 and its receptors in human bladder cancer.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21364580","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22576740","id":"PMC_22576740","title":"Regulation of HRG-β1-induced proliferation, migration and invasion of MCF-7 cells by upregulation of GPR30 expression.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/22576740","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31685488","id":"PMC_31685488","title":"MCLA-128 Fights NRG1 Fusion-Positive Cancers.","date":"2019","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/31685488","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14672197","id":"PMC_14672197","title":"Effects of corn silage hybrid and dietary concentration of forage NDF on digestibility and performance by dairy cows.","date":"2003","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/14672197","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35247506","id":"PMC_35247506","title":"Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.","date":"2022","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35247506","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22974608","id":"PMC_22974608","title":"Aberrant high expression of NRG1 gene in Hirschsprung disease.","date":"2012","source":"Journal of pediatric surgery","url":"https://pubmed.ncbi.nlm.nih.gov/22974608","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33541789","id":"PMC_33541789","title":"Roles and mechanisms of NRG1 in modulating the pathogenesis of NAFLD through ErbB3 signaling in hepatocytes (NRG1 modulates NAFLD through ErbB3 signaling).","date":"2021","source":"Obesity research & clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/33541789","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37678511","id":"PMC_37678511","title":"HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.","date":"2023","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37678511","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34023356","id":"PMC_34023356","title":"NFKB2 inhibits NRG1 transcription to affect nucleus pulposus cell degeneration and inflammation in intervertebral disc degeneration.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/34023356","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26534905","id":"PMC_26534905","title":"Polymorphisms of dopamine pathway genes NRG1 and LMX1A are associated with cognitive performance in bipolar disorder.","date":"2015","source":"Bipolar disorders","url":"https://pubmed.ncbi.nlm.nih.gov/26534905","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38175774","id":"PMC_38175774","title":"Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38175774","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12145742","id":"PMC_12145742","title":"Neuregulin 1 and susceptibility to schizophrenia.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12145742","citation_count":1264,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1350381","id":"PMC_1350381","title":"Identification of heregulin, a specific activator of p185erbB2.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1350381","citation_count":992,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18583979","id":"PMC_18583979","title":"Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18583979","citation_count":817,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19632177","id":"PMC_19632177","title":"Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19632177","citation_count":805,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8096067","id":"PMC_8096067","title":"Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8096067","citation_count":713,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7514177","id":"PMC_7514177","title":"Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7514177","citation_count":554,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1348215","id":"PMC_1348215","title":"Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1348215","citation_count":530,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16767099","id":"PMC_16767099","title":"Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16767099","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9553078","id":"PMC_9553078","title":"Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9553078","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12478479","id":"PMC_12478479","title":"Association of neuregulin 1 with schizophrenia confirmed in a Scottish population.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12478479","citation_count":415,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17336907","id":"PMC_17336907","title":"Notch signaling is essential for ventricular chamber development.","date":"2007","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/17336907","citation_count":403,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7556068","id":"PMC_7556068","title":"Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.","date":"1995","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7556068","citation_count":357,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16442083","id":"PMC_16442083","title":"Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology.","date":"2006","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16442083","citation_count":341,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9168115","id":"PMC_9168115","title":"Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9168115","citation_count":340,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19736351","id":"PMC_19736351","title":"Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation.","date":"2009","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/19736351","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9342050","id":"PMC_9342050","title":"Isoform-specific expression and function of neuregulin.","date":"1997","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9342050","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16618933","id":"PMC_16618933","title":"Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16618933","citation_count":323,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12646923","id":"PMC_12646923","title":"Segregation of receptor and ligand regulates activation of epithelial growth factor receptor.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12646923","citation_count":308,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15162166","id":"PMC_15162166","title":"Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.","date":"2004","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15162166","citation_count":305,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53749,"output_tokens":8968,"usd":0.147884},"stage2":{"model":"claude-opus-4-6","input_tokens":12732,"output_tokens":4445,"usd":0.262178},"total_usd":0.901614,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66436,"output_tokens":14720,"usd":0.210054},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":18703,"output_tokens":3766,"usd":0.281498}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"ErbB-2 forms heterodimers with EGF receptor (ErbB-1) and NDF/NRG1 receptors (ErbB-3 and ErbB-4), acting as a pan-ErbB auxiliary subunit that decelerates ligand dissociation rates and enhances binding affinity for both EGF and NDF, thereby potentiating and prolonging activation of MAP kinase (ERK) and c-Jun kinase (SAPK) signaling pathways.\",\n      \"method\": \"Co-immunoprecipitation, endoplasmic reticulum-trapped antibody to block ErbB-2 surface delivery, kinetic binding assays, kinase activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional experiments with multiple orthogonal methods, replicated across cell types\",\n      \"pmids\": [\"8617201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NDF/NRG1 binds with high affinity (Kd ~10^-9 M) to Neu/HER-2 in mammary tumor cells, inducing tyrosine phosphorylation of Neu and association with phosphatidylinositol 3'-kinase; binding requires both Neu and an additional cell-type-specific co-factor, as ovarian cells overexpressing Neu do not show covalent cross-linking to NDF.\",\n      \"method\": \"Radiolabeled NDF cross-linking, direct binding analysis, monoclonal antibody blocking, PI3K co-immunoprecipitation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding assays with mutagenic/antibody blocking and multiple cell line validation\",\n      \"pmids\": [\"8096177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NRG1 alpha and beta isoforms exert distinct mitogenic effects on keratinocytes; NRG1-beta isoforms bind ErbB-3 with higher affinity (Kd = 2.2 nM) and induce greater proliferation than alpha isoforms, establishing ErbB-3 as the direct binding receptor (no ErbB-4 expressed in these cells).\",\n      \"method\": \"Radioligand binding assays, receptor identification by RT-PCR/immunoprecipitation, proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding assays combined with receptor expression profiling and functional readout\",\n      \"pmids\": [\"7731691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GGF/NRG1 acts as a mitogen and survival factor for oligodendrocyte progenitors by activating ErbB2, ErbB3, and ErbB4 receptors; high levels of GGF reversibly inhibit differentiation and lineage commitment, with cortical neurons releasing NRG1 as a soluble paracrine mitogen specifically blocked by anti-NRG1 antibodies.\",\n      \"method\": \"Cell proliferation assays, receptor phosphorylation assays, antibody blocking, serum-free survival assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods with defined cellular phenotype and receptor identification\",\n      \"pmids\": [\"8780647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GGF/NRG1 expressed by migrating cortical neurons promotes their migration along radial glial fibers and maintains radial glial cell elongation via ErbB2 receptor signaling; NRG1 regulation of radial glial development is mediated in part through brain lipid-binding protein (BLBP).\",\n      \"method\": \"In vivo conditional ErbB2 receptor loss-of-function, antibody blocking, cortical slice migration assays, BLBP expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and pharmacological loss-of-function with defined cellular migration phenotype\",\n      \"pmids\": [\"9342043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NDF/NRG1 signaling in prostate cancer cells (LNCaP) occurs through ErbB3-ErbB2 crosstalk (without ErbB1 involvement) and activates PI3-K, ERK/MAPK, mHOG/p38, and JNK/SAPK pathways but not PLCgamma or STAT family; ErbB3 forms a striking 'activation complex' with PI3-K upon NDF stimulation.\",\n      \"method\": \"Receptor phosphorylation, co-immunoprecipitation, pathway-specific kinase assays, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive signaling dissection with multiple pathway readouts and co-IP\",\n      \"pmids\": [\"9400997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Schwann cells express NRG1 (NDF and SMDF/n-ARIA isoforms encoding transmembrane forms), secrete neuregulin protein (~45 kDa), and show constitutive activation of ErbB3, demonstrating an autocrine NRG1 loop; anti-NRG1 antibody blocks Schwann cell mitogenic responses not only to NRG1 but also to bFGF, HGF, and TGF-beta1.\",\n      \"method\": \"RT-PCR isoform characterization, ELISA for secreted NRG1, ErbB3 phosphorylation assay, antibody neutralization of mitogen responses\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods demonstrating autocrine loop with functional consequence\",\n      \"pmids\": [\"9417836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"HRG-beta2 (NRG1) stimulates tyrosine phosphorylation of ErbB2, ErbB3, and ErbB4, induces Shc phosphorylation and Shc-Grb2 complex formation (coupling to Ras), forms receptor-Shc complexes with ErbB2-4, and causes ErbB3 association with PI3-kinase; Grb2 associates with ErbB2 and ErbB4 but not ErbB3 immunoprecipitates, revealing mechanistic differences in Ras pathway coupling.\",\n      \"method\": \"Co-immunoprecipitation, tyrosine phosphorylation assays, Grb2/Shc pulldown, PI3K association assay\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple co-IP and biochemical assays in breast cancer cells with defined signaling pathway\",\n      \"pmids\": [\"9019162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Erbin, via its PDZ domain, binds to and stabilizes ErbB2 protein; loss of Erbin destabilizes ErbB2 and compromises NRG1 signaling, resulting in hypomyelination of peripheral nerves and aberrant Remak bundle formation in Schwann cells.\",\n      \"method\": \"Erbin knockout and PDZ-domain-deletion mouse models, protein stability assays, sciatic nerve morphology, nerve conduction velocity, immunoprecipitation of Erbin-ErbB2 complex\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function mouse models with mechanistic biochemical follow-up and functional phenotype\",\n      \"pmids\": [\"19458253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NRG1 isoform expression is regulated by neuronal activity: neuronal activity selectively increases type I and type IV NRG1 levels; type IV regulation requires a CRE cis-element in the 5' UTR that binds CREB. Isoforms I, II, and III are predominantly expressed in excitatory neurons.\",\n      \"method\": \"Neuronal activity manipulation, quantitative RT-PCR across brain regions and ages, CRE element mutation, CREB binding assay, cell-type-specific expression analysis\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of promoter regulation with mutagenesis and ChIP-like binding assays\",\n      \"pmids\": [\"21653853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"p63 transcription factor in basal mammary epithelial cells directly activates Nrg1 transcription; NRG1 then signals in a paracrine fashion to luminal cells via ERBB4/STAT5A, driving luminal progenitor cell maturation and lactation; genetic deletion of p63 in basal cells causes lactation failure due to loss of this NRG1-mediated basal-to-luminal signal.\",\n      \"method\": \"Conditional Trp63 knockout in adult mammary basal cells, ChIP for p63 on Nrg1 promoter, ERBB4/STAT5A phosphorylation assays, mammary gland phenotyping\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with direct transcriptional mechanism (ChIP) and signaling pathway readout\",\n      \"pmids\": [\"24412575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DISC1 in cortical interneurons inhibits NRG1-induced ErbB4 activation, likely through competitive inhibition of ErbB4 binding to PSD95; interneuronal DISC1 modulates NRG1-ErbB4-mediated fast-spiking interneuron–pyramidal neuron circuit function.\",\n      \"method\": \"Cell-type-specific gene knockdown/overexpression in vitro and in vivo, DISC1 mutant mouse model, ErbB4 phosphorylation assays, co-immunoprecipitation of ErbB4-PSD95, electrophysiological recording\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models with biochemical mechanism and electrophysiological functional readout\",\n      \"pmids\": [\"26656849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A RET-ER81-NRG1 signaling pathway in mechanosensory neurons controls Pacinian corpuscle formation; RET maintains ER81 expression, ER81 drives expression of specific NRG1 isoforms (distinct from those required for myelinating Schwann cell communication), and these isoforms mediate axon-nonmyelinating Schwann cell interactions required for corpuscle development.\",\n      \"method\": \"Conditional ER81 and Nrg1 knockout mice, Pacinian corpuscle morphology, myelination analysis, NRG1 isoform expression profiling\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic loss-of-function with isoform-specific mechanistic dissection\",\n      \"pmids\": [\"27707970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"VAMP2-NRG1 fusion protein is membrane-bound, displays the EGF-like domain of NRG1 extracellularly, and stimulates phosphorylation of ERBB2 and ERBB3 and downstream AKT and ERK, promoting anchorage-independent colony formation; this confirms NRG1 fusion proteins act as constitutive ERBB2/ERBB3 pathway activators.\",\n      \"method\": \"Immunoblotting for ERBB2/ERBB3/AKT/ERK phosphorylation, soft agar anchorage-independent growth assay, RT-PCR and genomic DNA fusion confirmation\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional reconstitution with signaling and growth assays\",\n      \"pmids\": [\"26134228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD74-NRG1 fusion promotes phosphorylation of ErbB2/ErbB3, activates PI3K/Akt/NF-κB signaling, and induces NF-κB-dependent IGF2 secretion and IGF1R phosphorylation, forming an IGF2 autocrine/paracrine circuit that drives cancer stem cell-like properties and tumor initiation.\",\n      \"method\": \"ERBB2/3 phosphorylation assays, NF-κB reporter, IGF2/IGF1R phosphorylation, limiting dilution xenograft assay, sphere formation, pharmacological inhibition of ErbB2/PI3K/NF-κB/IGF2\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pathway inhibition experiments with in vivo xenograft validation\",\n      \"pmids\": [\"26837769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC3A2-NRG1 fusion protein comprises the SLC3A2 transmembrane domain and NRG1 EGF-like domain; it binds ERBB3 and ERBB4, promotes ERBB2-ERBB3 heterocomplex formation, and activates PI3K-AKT and MAPK signaling to drive colony formation and tumor growth; dual inhibition of ERBB2 and ERBB3 (but not single inhibition) effectively blocks all downstream signaling.\",\n      \"method\": \"Ligand-receptor binding assay, co-immunoprecipitation, ERBB2/3 phosphorylation, siRNA knockdown of ERBB2/ERBB3, pertuzumab/lumretuzumab/afatinib inhibition, colony formation, xenograft tumor models\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — binding assays, genetic knockdown, and pharmacological inhibition with in vivo validation\",\n      \"pmids\": [\"29959202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Oncogenic KRAS mutation enhances MEK1/2-ERK1/2 activity, which increases ADAM17 metalloprotease activity, causing shedding/cleavage of NRG1 from SLC3A2-NRG1 fusion protein; this shed NRG1 then activates ERBB2-ERBB3 heterocomplex phosphorylation and PI3K/Akt/mTOR signaling, synergizing with KRAS mutation to promote tumor growth.\",\n      \"method\": \"MEK inhibitor and ADAM17 inhibitor treatment, ERBB2/ERBB3/AKT/ERK phosphorylation assays, xenograft and lung orthotopic mouse models, apoptosis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection with pharmacological inhibition confirmed in multiple in vivo models\",\n      \"pmids\": [\"34743207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LH-induced NRG1 type III expression in granulosa cells is driven through ERK1/2 and C/EBPβ; secreted NRG1 binds ERBB3/ERBB2 complexes on granulosa and cumulus cells, selectively activates AKT phosphorylation, and synergizes with amphiregulin (AREG) to enhance ERK1/2 phosphorylation and progesterone production, and improves oocyte maturation competence.\",\n      \"method\": \"Western blotting for NRG1 protein forms, ERBB2/ERBB3 phosphorylation, granulosa cell culture with pathway inhibitors, oocyte developmental competence assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — signaling dissection with multiple receptor and kinase assays and functional oocyte readout\",\n      \"pmids\": [\"21047912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endocardial Nrg1 signals to myocardial ErbB2 to activate phospho-ERK (pErk), which controls cardiomyocyte oriented cell division, trabecula formation, Pard3/Crumbs2 polarity protein expression, and cytoskeletal actin organization; Nrg1 also regulates an EMT-like process involving cardiomyocyte migration and G2/M cell cycle progression; Nrg1-dependent pErk modulates Yap1 nuclear-cytoplasmic distribution.\",\n      \"method\": \"Cardiac-specific Nrg1 knockout and overexpression mice, confocal imaging, transcriptomics, ErbB2/pErk biochemical assays, Pard3/Crumbs2 immunofluorescence\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation with biochemical mechanism and structural/transcriptomic validation\",\n      \"pmids\": [\"37846569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TrkB interacts with ErbB4 (NRG1 receptor) in cortical neurons; NRG1 stimulation increases TrkB-ErbB4 interaction, promotes BDNF release via ErbB4 activation, and subsequently triggers BDNF/TrkB-dependent NR2B NMDA receptor subunit phosphorylation; TrkB inhibition or knockout abolishes NRG1-induced NR2B activation.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay for TrkB-ErbB4 interaction, TrkB inhibitor (K252a), TrkB siRNA and TrkB-/- neurons, BDNF neutralizing antibody, ErbB4 inhibitor (AG1478), phospho-NR2B Western blot\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (PLA, co-IP, genetic KO, pharmacological inhibition) with clear pathway dissection\",\n      \"pmids\": [\"25052836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Nedd4l E3 ubiquitin ligase promotes ubiquitination and degradation of NRG1 protein in the medial prefrontal cortex; stress susceptibility in mice is associated with increased Nedd4l expression and increased NRG1 ubiquitination (without changes in NRG1 mRNA), leading to decreased NRG1 protein; overexpression of NRG1 or knockdown of Nedd4l in mPFC attenuates depression-like behaviors.\",\n      \"method\": \"Ubiquitination assay, Nedd4l overexpression/knockdown in mPFC (viral vectors), NRG1 protein level measurement, chronic social defeat stress behavioral model, RNA sequencing\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — E3 ligase-substrate ubiquitination demonstrated biochemically with in vivo behavioral validation\",\n      \"pmids\": [\"32703967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cancer-associated fibroblast (CAF)-derived NRG1 activates ERBB2 and ERBB3 receptor tyrosine kinases on pancreatic cancer cells to support KRAS*-independent growth; KRAS* extinction upregulates ERBB2 and ERBB3 expression, making cancer cells dependent on CAF-secreted NRG1 as a survival factor; dual ERBB2/3 or NRG1 inhibition abolishes this bypass mechanism.\",\n      \"method\": \"Genetic KRAS* extinction (siRNA/pharmacological), ERBB2/ERBB3 expression and phosphorylation assays, NRG1 knockdown in CAFs, co-culture systems, mouse and human PDAC models, KRASG12D inhibitor combination experiments\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic paracrine pathway established with genetic and pharmacological tools in multiple models\",\n      \"pmids\": [\"37775182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In mammary adenocarcinoma cells, progestin (MPA) upregulates HRG/NRG1 mRNA and protein; HRG acts as a mediator of MPA-induced growth (antisense HRG inhibits MPA-induced proliferation); HRG and MPA both induce tyrosine phosphorylation of ErbB-2 and ErbB-3; HRG's proliferative effect requires a functional IGF-IR (antisense IGF-IR completely abolishes HRG mitogenesis).\",\n      \"method\": \"Antisense oligodeoxynucleotide knockdown of HRG, ErbB-2, and IGF-IR; tyrosine phosphorylation assays; cell proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antisense knockdown of multiple pathway components with defined proliferation phenotype\",\n      \"pmids\": [\"10597237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HRG/NRG1-dependent cellular transformation requires mTORC2 (via Rictor); HRG activates PI3K and mTORC1 through mTORC2-mediated AKT phosphorylation at both T308 and S473; genetic elimination of Rictor abolishes mTORC1 activation and HRG-mediated anchorage-independent growth.\",\n      \"method\": \"Rapamycin and INK-128 mTOR inhibitor comparison, Rictor siRNA knockdown, AKT phosphorylation (T308/S473) assays, anchorage-independent growth assay\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological dissection of mTOR complexes with defined transformation phenotype\",\n      \"pmids\": [\"24615340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Zenocutuzumab (HER2×HER3 bispecific antibody) blocks NRG1 binding to HER3, inhibits HER3 and AKT phosphorylation, induces apoptosis markers, and inhibits growth of NRG1 fusion-positive cancer cells and xenografts; this establishes that NRG1 fusions drive signaling primarily through HER3-HER2 heterodimerization.\",\n      \"method\": \"HER3/AKT phosphorylation assays, apoptosis markers, isogenic and patient-derived cell lines, xenograft models, clinical patient responses\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo mechanistic validation corroborated by clinical responses\",\n      \"pmids\": [\"35135829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NRG1 and HGF provide resistance to MEK inhibition in uveal melanoma; trametinib enhances responsiveness to NRG1 (via ERBB3) and HGF (via cMET); NRG1-mediated resistance operates through sustained AKT activation; targeting ERBB3 or AKT overcomes NRG1-conferred resistance.\",\n      \"method\": \"Growth factor resistance screening, AKT/ERBB2 phosphorylation assays, ERBB3/cMET antibody inhibition, AKT inhibitor treatment, fibroblast conditioned medium experiments, xenograft liver models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with pharmacological and antibody tools in cell and in vivo models\",\n      \"pmids\": [\"25952648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRG1 signals through ERBB3 in enteric progenitors (demonstrated by ErbB3-conditional knockout mouse); biallelic ERBB3 or ERBB2 mutations in humans result in aganglionosis, hypoganglionosis, and intestinal smooth muscle abnormalities; patient-derived fibroblasts with identified variants show decreased receptor expression or altered phosphorylation.\",\n      \"method\": \"Conditional ErbB3-deficient mouse model, single-cell RNA sequencing, patient fibroblast expression/phosphorylation assays, trio-exome sequencing of patients\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with human genetic and biochemical validation\",\n      \"pmids\": [\"33497358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endothelial autocrine NRG1/ERBB4 signaling (demonstrated by endothelial-specific ERBB4 knockout) modulates early hypertrophic and fibrotic responses during cardiac remodeling; endothelial NRG1 controls expression of hypertrophic and fibrotic pathway genes in cultured endothelial cells.\",\n      \"method\": \"EC-specific Erbb4 knockout mice, transverse aortic constriction, angiotensin II treatment, myocardial infarction models, RNA sequencing of endothelial cells\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific genetic knockout with defined cardiac phenotype and transcriptomic mechanism\",\n      \"pmids\": [\"32618511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRG1 expressed by foxd3-positive neural crest-derived cells (NCdC) in the zebrafish regenerating fin regulates macrophage recruitment and polarization via the NRG1/ErbB pathway, contributing to blastema formation and fin regeneration.\",\n      \"method\": \"Genetic depletion of NCdC, chemical ErbB inhibition, single-cell RNA sequencing, live imaging of triple transgenic zebrafish\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with scRNA-seq mechanistic validation\",\n      \"pmids\": [\"34732706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RET and NRG1 genetic variants interact functionally in Hirschsprung disease: NRG1 (ErbB2 ligand) inhibits GDNF-induced neuronal differentiation of mouse enteric neural crest cells, while GDNF negatively regulates NRG1 signaling by down-regulating ErbB2 expression, establishing a reciprocal signaling balance critical for ENS neurogenesis/gliogenesis.\",\n      \"method\": \"Mouse neural crest cell isolation and culture, NRG1 and GDNF treatment, ErbB2 expression assay, neuronal differentiation monitoring, conditional logistic regression for genetic interaction\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab cell culture experiments demonstrating reciprocal pathway interaction, limited mechanistic depth\",\n      \"pmids\": [\"23400839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NRG1 secreted by adipocyte precursors (PDGFRA+ inflammatory cancer-associated fibroblasts) activates HER3 (ERBB3) signaling on tumor cells to confer paracrine resistance to FGFR inhibition; NRG1 knockdown in adipocyte precursors abolishes resistance; pertuzumab (anti-HER2, blocking NRG1/HER3 axis) reverses resistance in vitro and in vivo.\",\n      \"method\": \"NRG1 knockdown in adipocyte precursors, HER3 phosphorylation assays, pertuzumab treatment, xenograft mouse model survival, single-cell RNA sequencing\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown and pharmacological blockade with in vivo xenograft validation\",\n      \"pmids\": [\"38175774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Stromal NRG1 from cancer-associated fibroblasts (CAFs) activates HER3 in luminal breast cancer cells in a paracrine manner; NRG1 also acts in a HER3-independent manner within CAFs to induce a migratory and pro-fibrotic phenotype; HAS2 (Hyaluronan Synthase 2) is identified as correlated with and supporting NRG1 signaling in CAFs.\",\n      \"method\": \"Conditioned medium experiments, HER3 phosphorylation assays, CAF transcriptomic profiling, NRG1-CAF co-culture systems\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab with multiple assays but limited mechanistic depth for HER3-independent pathway\",\n      \"pmids\": [\"33692466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NRG1 fusions can activate downstream signaling and tumor cell growth through HER4 independent of other HER family members, and through EGFR-HER3 signaling; pan-HER inhibition (including HER4 and EGFR) is more effective than selective HER2-HER3 targeting in NRG1 fusion-positive cancer models.\",\n      \"method\": \"Ba/F3 engineered cell models expressing combinations of HER family members with NRG1 fusions, receptor phosphorylation assays, growth inhibition assays, cetuximab/trastuzumab/pertuzumab combination experiments, pan-HER TKI comparison\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — engineered isogenic cell models with multiple receptor combinations and pharmacological validation\",\n      \"pmids\": [\"37678511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NRG1-Fc fusion protein activates AKT signaling in the liver, suppresses hepatic gluconeogenesis, potently induces FGF21 secretion (which is dispensable for metabolic effects), and directly depolarizes hypothalamic POMC neurons to increase firing rate, collectively lowering blood glucose and food intake in obese mice.\",\n      \"method\": \"AKT phosphorylation in liver, glucose and insulin tolerance tests, FGF21 ELISA, FGF21 knockout mouse, electrophysiology of POMC neurons, NRG1-Fc vs. native NRG1 pharmacokinetic comparison\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple tissue-level mechanisms dissected with genetic (FGF21 KO) and electrophysiological approaches\",\n      \"pmids\": [\"29515030\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NRG1 (neuregulin-1) is a growth factor ligand that, depending on isoform and cellular context, binds directly to ERBB3 or ERBB4 receptor tyrosine kinases and induces their heterodimerization with ERBB2, activating downstream PI3K-AKT, RAS-ERK/MAPK, and related pathways; ERBB2 acts as a co-receptor that amplifies NRG1 signaling by decelerating ligand dissociation; NRG1 isoforms are regulated by neuronal activity via CRE/CREB-mediated transcription, and NRG1 protein is post-translationally regulated by Nedd4l-mediated ubiquitination and by ADAM17-mediated ectodomain shedding; NRG1 controls Schwann cell myelination (stabilized by Erbin-ErbB2 interaction), oligodendrocyte proliferation, neuronal migration along radial glia, Pacinian corpuscle development (via a RET-ER81-NRG1 axis), cardiomyocyte trabeculation and cell cycle progression (via endocardial-to-myocardial ErbB2-ERK signaling), lactogenesis (via p63-driven basal-to-luminal ERBB4/STAT5A signaling), and enteric nervous system development (via ERBB3); oncogenic NRG1 gene fusions present the EGF-like domain on the cell surface to constitutively activate ERBB2-ERBB3 heterodimerization and downstream PI3K-AKT/NF-κB/MAPK signaling, and CAF-derived paracrine NRG1 mediates resistance to KRAS and FGFR inhibitors through ERBB2/ERBB3 activation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**EXCLUDE papers (not about canonical human/mammalian NRG1 protein):**\n- Papers [5], [7], [13] (retrieved corpus): Plant NRG1 (N REQUIRED GENE1) - Arabidopsis immune receptor helper NLR\n- Paper [20] (retrieved): HRG = Histidine-Rich Glycoprotein, different protein\n- Paper [24] (retrieved): Candida albicans Nrg1p transcriptional repressor - fungal protein, symbol collision\n- Papers [35], [46], [63], [70], [75], [76], [77], [83], [88] (retrieved): Histidine-Rich Glycoprotein (HRG)\n- Paper [64] (retrieved): Plant NRG1 (Nicotiana benthamiana)\n- Papers [73], [84], [93] (retrieved): NDF/NRG = neutral detergent fiber in animal nutrition\n- Papers [1]-[4] (additional curated, general cDNA/interactome papers not mechanistically about NRG1)\n- Papers [3], [4], [6], [11] (additional curated): Large interactome screens - minimal NRG1-specific mechanism\n- Papers [12], [16], [18], [21] (additional curated): General genomics resources\n- Paper [81] (retrieved): lncRNA paper targeting Nrg1, but about lncRNA mechanism primarily\n\nAll other papers are **KEEP** as they describe canonical mammalian NRG1 (neuregulin-1).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"NRG1 (heregulin/NDF) was purified as a 44-45 kDa glycoprotein ligand that specifically induces phosphorylation of p185erbB2/Neu receptor at picomolar concentrations, establishing NRG1 as the activating ligand for the ErbB2 receptor tyrosine kinase.\",\n      \"method\": \"Protein purification from conditioned medium, Scatchard binding analysis, chemical cross-linking with radiolabeled ligand, immunoprecipitation\",\n      \"journal\": \"Science / Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — two independent purification/binding studies, direct cross-linking showing NRG1-ErbB2 interaction\",\n      \"pmids\": [\"1350381\", \"1348215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Glial growth factors (GGF), mitogenic proteins for Schwann cells, are alternatively spliced isoforms of NRG1 and act as ligands for p185erbB2 receptor, with alternative splicing generating membrane-attached, intracellular and secreted signaling proteins.\",\n      \"method\": \"cDNA cloning, alternative splicing analysis, in situ hybridization, receptor binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular cloning with functional receptor binding validation, foundational isoform discovery\",\n      \"pmids\": [\"8096067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NDF (NRG1) binds with high affinity (Kd ~10^-9 M) to mammary cells via a complex requiring both ErbB2/Neu and an additional cellular co-receptor; ovarian cells overexpressing Neu did not show covalent cross-linking to NDF and lacked NDF-induced PI3-kinase association, indicating cell-type-specific receptor requirements.\",\n      \"method\": \"Radiolabeled NDF cross-linking, monoclonal antibody blocking, direct binding analysis, PI3-kinase co-immunoprecipitation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal binding and signaling assays demonstrating receptor complex requirement\",\n      \"pmids\": [\"8096177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Co-expression of ErbB2 and ErbB3 reconstitutes a high-affinity heregulin (NRG1) binding receptor; ErbB3 alone binds heregulin with lower affinity and shows little tyrosine phosphorylation, whereas the ErbB2/ErbB3 heterodimer generates robust tyrosine phosphorylation signaling. Chemical cross-linking confirmed direct interaction of heregulin with both ErbB2 and ErbB3 in the heterodimer.\",\n      \"method\": \"Receptor transfection/reconstitution, Scatchard binding analysis, 125I-heregulin cross-linking, immunoprecipitation, tyrosine phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution experiment with direct binding and phosphorylation assays, multiple controls\",\n      \"pmids\": [\"7514177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"HRG (NRG1) beta2 stimulates tyrosine phosphorylation of ErbB2, ErbB3, and ErbB4 in breast cancer cells, induces formation of Shc-Grb2 complexes and receptor-Shc complexes, and stimulates PI3-kinase association with ErbB3, revealing multiple inputs into Ras signaling; ErbB3 associates with PI3-kinase but Grb2 associates with ErbB2 and ErbB4 but not ErbB3, indicating mechanistic differences in Ras coupling among ErbB receptors.\",\n      \"method\": \"Tyrosine phosphorylation assays, co-immunoprecipitation, PI3-kinase association assays, cell proliferation assays\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays mapping distinct signaling connections downstream of NRG1\",\n      \"pmids\": [\"9019162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NRG1 beta isoforms bind ErbB-3 directly (Kd = 2.2 nM) and exert mitogenic effects on keratinocytes, whereas alpha isoforms bind the same receptor with lower affinity and produce minimal mitogenesis, demonstrating that different NRG1 isoforms elicit distinct growth regulatory effects through differential binding affinity to ErbB-3.\",\n      \"method\": \"Radioligand binding assays, mitogenesis assays, RT-PCR for receptor expression, keratinocyte culture\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding quantification combined with functional growth assays across multiple isoforms\",\n      \"pmids\": [\"7731691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"HRG (NRG1) induces HER2-HER3 heterodimerization; ATP-binding-site mutants demonstrate that HER2 transphosphorylates HER3 (but not vice versa), and HRG-induced HER3 transphosphorylation enhances SHC and PI3-kinase association and confers transforming activity to NIH 3T3 cells co-expressing HER2 and HER3.\",\n      \"method\": \"ATP-binding-site kinase-dead mutants, co-immunoprecipitation, NIH 3T3 transformation assay, PI3-kinase association assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — kinase-dead mutagenesis establishing directionality of transphosphorylation, transformation assay validating oncogenic mechanism\",\n      \"pmids\": [\"7556068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"ErbB-2 functions as a pan-ErbB auxiliary subunit by forming heterodimers with both ErbB-1 (EGFR) and NDF receptors (ErbB-3 and ErbB-4); ErbB-2 overexpression enhances binding affinities of both EGF and NDF by decelerating ligand dissociation rates, thereby prolonging and potentiating downstream ERK and SAPK/JNK signaling cascades. Removal of ErbB-2 from the cell surface almost completely abolished NDF binding.\",\n      \"method\": \"ErbB-2 overexpression, ER-trapped antibody to block cell surface delivery, kinetic binding analysis, co-immunoprecipitation, MAP kinase/JNK activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function ErbB-2 manipulation with quantitative kinetic binding measurements and downstream signaling readouts\",\n      \"pmids\": [\"8617201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GGF/neuregulin (NRG1) acts as a mitogen for pro-oligodendrocytes and oligodendrocytes, promotes their survival under serum-free conditions, and at high concentrations reversibly inhibits differentiation and lineage commitment; all three ErbB receptors (ErbB2, ErbB3, ErbB4) are expressed by oligodendrocyte progenitors and are activated by GGF, with relative abundance changing during differentiation. Cortical neurons release a soluble GGF-like mitogen for pro-oligodendrocytes that is blocked by anti-GGF antibodies.\",\n      \"method\": \"Cell culture proliferation/survival assays, antibody blocking, Western blot for ErbB receptor phosphorylation, neuron-conditioned medium experiments\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with receptor activation analysis and antibody blocking controls\",\n      \"pmids\": [\"8780647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GGF/neuregulin (NRG1) is expressed by migrating cortical neurons and promotes their migration along radial glial fibers; concurrently, GGF promotes maintenance and elongation of radial glial cells via ErbB2 receptor signaling. In the absence of ErbB2-mediated GGF signaling, radial glial development is abnormal. GGF regulation of radial glial development is mediated in part by brain lipid-binding protein (BLBP).\",\n      \"method\": \"In vivo mouse cortical development analysis, antibody inhibition, ErbB2 knockout analysis, BLBP expression studies\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and antibody-blocking experiments with defined cellular phenotypes\",\n      \"pmids\": [\"9342043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NRG1 isoform-specific functions in vivo: Type I neuregulin is required for generation of neural crest-derived neurons in cranial ganglia and for trabeculation of the heart ventricle, while Type III neuregulin plays an important role in early Schwann cell development, demonstrating that distinct NRG1 isoforms have non-redundant functions in development.\",\n      \"method\": \"Targeted isoform-specific gene mutations in mice, in situ hybridization, histological analysis of developmental phenotypes\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockout mice with distinct developmental phenotypes, replicated across multiple tissue systems\",\n      \"pmids\": [\"9342050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"NDF (NRG1) signaling in prostate cancer cells via ErbB3/ErbB2 heterodimers (not ErbB1) activates PI3-K, ERK/MAPK, mHOG/p38, and JNK/SAPK pathways but not PLCγ or STAT signaling; ErbB3-PI3-K association forms a striking 'activation complex' with multiple tyrosine-phosphorylated species. NDF inhibits LNCaP growth and induces epithelial-like morphological change in contrast to TGF-α.\",\n      \"method\": \"Immunoprecipitation, Western blot for phosphorylation, PI3-K activation assays, proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive signaling pathway mapping in a single cell line with biochemical assays\",\n      \"pmids\": [\"9400997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Schwann cells express NDF and SMDF/n-ARIA NRG1 mRNAs, secrete neuregulin protein (~45 kDa), and show constitutive activation of ErbB3 receptor, demonstrating an autocrine neuregulin loop in Schwann cells. An anti-neuregulin antibody inhibits Schwann cell proliferation in response to neurons and also blocks proliferation induced by unrelated mitogens including bFGF, HGF, and TGF-β1, indicating that neuregulin autocrine signaling is a convergence point for multiple mitogenic signals.\",\n      \"method\": \"RT-PCR, ELISA for neuregulin secretion, ErbB3 activation assays, antibody blocking of proliferation\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct secretion measurement and antibody blocking establishing autocrine loop with functional consequence\",\n      \"pmids\": [\"9417836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Neuregulin-2 (NRG-2) is a distinct gene product (not NRG1) whose EGF-like domain binds ErbB3 and ErbB4; however, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles than NRG1, indicating that NRG1 and NRG-2 mediate distinct biological processes despite shared receptor binding.\",\n      \"method\": \"Ligand binding assays, receptor phosphorylation profiling, expression analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative binding and phosphorylation analysis distinguishing NRG1 from NRG2\",\n      \"pmids\": [\"9168115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NRG1 (as rhGGF2) promotes survival, inhibits apoptosis, and induces hypertrophic growth of neonatal and adult rat cardiac myocytes via ErbB2 and ErbB4 receptors expressed on these cells. NRG1 mRNA is produced by coronary microvascular endothelial cells and is upregulated by endothelin-1, establishing a paracrine endothelial-to-cardiomyocyte NRG1 signaling axis.\",\n      \"method\": \"Isolated cardiomyocyte cultures, proliferation/apoptosis assays, receptor phosphorylation, RT-PCR for NRG1 in endothelial cells, endothelin-1 stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays (proliferation, survival, hypertrophy) in primary cardiomyocytes with receptor identification\",\n      \"pmids\": [\"9553078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MPA (progestin) induces HRG (NRG1) mRNA expression in mouse mammary tumor cells; antisense oligonucleotides to HRG inhibit MPA-induced cell growth, demonstrating HRG acts as a mediator of progestin-induced proliferation. Both HRG and MPA proliferative effects require ErbB-2 and a functional IGF-1 receptor.\",\n      \"method\": \"Antisense oligodeoxynucleotides, RT-PCR, tyrosine phosphorylation assays, proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — antisense knockdown with proliferation readout, single lab study\",\n      \"pmids\": [\"10597237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In human ovarian carcinoma cells, NRG1 (HRG) activates HER3 independently of HER2 in some cell lines; EGF preferentially induces EGFR-HER2 heterodimers while HRG preferentially activates HER3/HER4 depending on receptor abundance; EGF and HRG mediate cell growth through distinct receptor complexes (EGFR/HER2 vs. HER4), while HER3 alone does not mediate growth even when phosphorylated.\",\n      \"method\": \"Receptor co-immunoprecipitation, phosphorylation assays, proliferation assays across cell lines with different receptor expression\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparative analysis across multiple cell lines with distinct receptor compositions\",\n      \"pmids\": [\"10733345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"NRG1 was identified as a susceptibility gene for schizophrenia by genome-wide linkage scan and haplotype-association analysis; NRG1 hypomorphic mice have fewer functional NMDA receptors, and ErbB4 receptor reduction produces behavioral phenotypes overlapping with mouse models of schizophrenia. The behavioral phenotypes of NRG1 hypomorphs are partially reversible with clozapine treatment.\",\n      \"method\": \"Genome-wide linkage scan, haplotype association, NRG1 hypomorph mouse behavioral analysis, NMDA receptor quantification, clozapine pharmacological rescue\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic hypomorph mouse model with NMDA receptor quantification and pharmacological rescue\",\n      \"pmids\": [\"12145742\", \"12478479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In differentiated human airway epithelia, NRG1 (heregulin-alpha) is segregated exclusively to the apical membrane while its receptors ErbB2-4 localize to the basolateral membrane, physically separated by tight junctions. Upon mechanical injury, heregulin-alpha activates ErbB2 in cells at the wound edge, promoting restoration of epithelial integrity. This ligand-receptor segregation mechanism regulates NRG1/ErbB signaling.\",\n      \"method\": \"Confocal microscopy of polarized epithelia, mechanical injury assays, receptor phosphorylation after injury, tight junction manipulation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization imaging with functional wound-healing consequence, strong mechanistic link\",\n      \"pmids\": [\"12646923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"αvβ3 integrin regulates NRG1 (HRG)-induced ERK1/2 MAPK activation and cell proliferation; HRG promotes αvβ3 expression through its downstream effector CYR61; blockade of αvβ3 impairs HRG-promoted ERK1/2 hyperactivation without altering AKT activation, and αvβ3 antagonists decrease S- and G2/M-phase subpopulations with increased p27Kip1 nuclear translocation.\",\n      \"method\": \"αvβ3 antagonists, antisense oligodeoxynucleotides, flow cytometry, ERK/AKT phosphorylation assays, p27Kip1 nuclear translocation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — multiple pharmacological and antisense tools but single lab\",\n      \"pmids\": [\"15782133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In schizophrenia postmortem prefrontal cortex, NRG1-induced activation of ErbB4 is markedly increased compared to controls despite no change in NRG1 or ErbB4 protein levels. This hyperactivation correlates with substantially increased ErbB4-PSD95 interactions (PSD95 facilitates ErbB4 activation). NRG1 stimulation suppresses NMDA receptor activation in human prefrontal cortex, and this suppression is more pronounced in schizophrenia, suggesting NRG1-ErbB4 hyperactivation contributes to NMDA receptor hypofunction.\",\n      \"method\": \"Postmortem tissue stimulation with NRG1, ErbB4 phosphorylation assays, PSD95-ErbB4 co-immunoprecipitation, NMDA receptor activation measurement\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel postmortem tissue stimulation approach with co-IP and functional NMDA receptor readout in human tissue\",\n      \"pmids\": [\"16767099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Disease-associated SNPs in the 5' upstream region of NRG1 regulate mRNA expression of specific isoforms: SNP8NRG221132 interacts with schizophrenia diagnosis to affect Type I NRG1 (34% increase in schizophrenia), and SNP8NRG243177 within the risk haplotype is associated with expression of the novel Type IV NRG1 isoform. Bioinformatic analysis reveals these SNPs alter binding sites for SRF, MYT1, and HMG Box Protein-1 transcription factors.\",\n      \"method\": \"Quantitative RT-PCR of postmortem hippocampus, genotype-expression correlation, bioinformatic promoter analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — expression-genotype correlation in postmortem tissue with bioinformatic analysis of TF binding\",\n      \"pmids\": [\"16618933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Notch1 signaling in ventricular endocardium directly regulates EphrinB2 expression (a direct Notch transcriptional target), which acts upstream of NRG1 in trabeculation; NRG1 signaling mediates cardiomyocyte differentiation downstream of Notch-EphrinB2, while BMP10 independently regulates cardiomyocyte proliferation. RBPJk/Notch1 mutants show attenuated NRG1 expression and signaling.\",\n      \"method\": \"RBPJk and Notch1 mutant mice, NRG1 expression analysis, exogenous NRG1 rescue of differentiation defects in cultured RBPJk mutant hearts, luciferase reporter assays for EphrinB2 as Notch target\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with rescue experiments placing NRG1 downstream of Notch-EphrinB2 in cardiac trabeculation\",\n      \"pmids\": [\"17336907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NRG1 induces mononucleated (but not binucleated) cardiomyocytes to proliferate via ErbB4 signaling; genetic inactivation of ErbB4 reduces cardiomyocyte proliferation while increased ErbB4 expression enhances it. Injection of NRG1 in adult mice induces cardiomyocyte cell-cycle activity and promotes myocardial regeneration, improving cardiac function after myocardial infarction without contribution from undifferentiated progenitor cells.\",\n      \"method\": \"ErbB4 genetic knockout/overexpression, NRG1 injection in adult mice, cardiomyocyte cell cycle analysis, post-infarction cardiac function measurement, cell lineage tracing\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function genetic models with in vivo functional readouts and lineage tracing\",\n      \"pmids\": [\"19632177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NRG1/ERBB3 signaling inhibits melanocyte maturation and promotes undifferentiated, migratory, and proliferative characteristics; ERBB3 signaling was necessary and sufficient to inhibit differentiation of later-stage melanocytes in culture. NRG1-treated melanocytes showed increased proliferation, invasion, and altered morphology with decreased differentiation gene expression and increased proliferation/metastasis gene levels.\",\n      \"method\": \"ERBB3 knockout analysis in embryos, NRG1 treatment of cultured melanocytes, proliferation/invasion assays, gene expression profiling\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic analysis combined with in vitro NRG1 treatment with multiple functional readouts\",\n      \"pmids\": [\"19659570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Erbin, a protein with LRR and PDZ domains that interacts specifically with ErbB2, is necessary for NRG1 signaling and myelination of the peripheral nervous system. Erbin null mice show hypomyelination and aberrant unmyelinated axon ensheathing; Erbin's PDZ domain binds and stabilizes ErbB2, which is required for NRG1 signaling. Loss of Erbin destabilizes ErbB2 protein and compromises NRG1 signaling.\",\n      \"method\": \"Erbin knockout and PDZ-domain-deleted knockin mice, sciatic nerve histology, ErbB2 protein stability assays, nerve conduction velocity measurement, siRNA knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse models with molecular mechanism (PDZ-ErbB2 stabilization) and physiological readouts\",\n      \"pmids\": [\"19458253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LH induces expression of Type III NRG1 transcripts in granulosa cells in an ERK1/2 and C/EBPβ-dependent manner during ovulation. NRG1 binds ERBB3/ERBB2 complexes on granulosa and cumulus cells, selectively stimulates AKT/PKB phosphorylation over ERK1/2, and synergizes with amphiregulin (AREG) to enhance ERK1/2 phosphorylation, progesterone production, and oocyte developmental competence.\",\n      \"method\": \"Western blotting, granulosa cell culture, AKT/ERK phosphorylation assays, progesterone RIA, oocyte developmental competence assay, conditional ERK1/2 inhibition\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined signaling pathways with multiple functional readouts in physiological ovulatory model\",\n      \"pmids\": [\"21047912\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NRG1 isoform expression in the brain is regulated by neuronal activity; activity causes significant increases in Type I and Type IV NRG1. Type IV NRG1 upregulation by neuronal activity requires a CRE cis-element in the 5' UTR that binds CREB transcription factor. Each NRG1 isoform (Types I-VI) shows a distinct developmental expression pattern and is regulated by distinct mechanisms.\",\n      \"method\": \"RT-PCR for isoform quantification, CREB binding site mutation, luciferase reporter assays, neuronal activity manipulation (KCl depolarization)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRE element mutagenesis with reporter assay establishing transcriptional mechanism for activity-dependent Type IV regulation\",\n      \"pmids\": [\"21653853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RET and NRG1 genetically interact in Hirschsprung disease; in mouse neural crest cells, NRG1 inhibits GDNF-induced neuronal differentiation and GDNF negatively regulates NRG1 signaling by downregulating ErbB2 receptor expression, indicating that the balance between NRG1/ErbB and RET/GDNF signaling is critical for enteric nervous system neurogenesis/gliogenesis.\",\n      \"method\": \"Mouse neural crest cell culture, NRG1 and GDNF treatment, neuronal differentiation assays, receptor expression analysis by Western blot, conditional logistic regression for genetic interactions\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional interaction in cell culture with receptor downregulation mechanism, single lab\",\n      \"pmids\": [\"23400839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"p63 transcription factor directly activates NRG1 gene transcription in mammary basal cells during pregnancy; basal cell NRG1 signals paracrinally to luminal cells via ERBB4, leading to STAT5A activation and luminal progenitor cell maturation for lactation. Genetic deletion of p63 exclusively in basal cells causes lactation failure due to failure of luminal cell proliferation and differentiation.\",\n      \"method\": \"Conditional p63 knockout in adult mammary basal cells, ChIP for p63 binding to Nrg1 promoter, ERBB4/STAT5A phosphorylation assays, mammary gland histology and functional lactation assay\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishes direct transcriptional regulation, conditional KO with defined cellular phenotype, signaling pathway validated\",\n      \"pmids\": [\"24412575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TrkB interacts with ErbB4 (the NRG1 receptor) and this interaction is increased following NRG1 treatment; NRG1 induces GABAR-mediated TrkB activation and BDNF release via ErbB4, which in turn phosphorylates NMDA receptor subunit NR2B. TrkB kinase inhibition or TrkB siRNA suppresses NRG1-induced NR2B activation, and TrkB-ErbB4 interaction is reduced in prefrontal cortex of schizophrenia subjects.\",\n      \"method\": \"Co-immunoprecipitation, proximity ligation assay, TrkB inhibitor K252a, TrkB siRNA, TrkB knockout neurons, BDNF neutralizing antibody, TrkB domain mutants\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, PLA, KO neurons, domain mutants) establishing TrkB-ErbB4 interaction and pathway\",\n      \"pmids\": [\"25052836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"mTORC2 is a necessary component of HRG (NRG1)/ErbB2-induced cellular transformation; HRG activates PI3-kinase and mTORC1, and mTORC2 regulates the AKT/TSC2/mTORC1 axis by controlling AKT phosphorylation at both T308 (PDK1-dependent) and S473 (mTORC2-dependent) sites. Elimination of Rictor (mTORC2 component) abolishes both mTORC1 activation and HRG-mediated anchorage-independent growth.\",\n      \"method\": \"mTOR inhibitors (rapamycin and INK-128), Rictor siRNA/knockout, AKT phosphorylation assays at multiple sites, anchorage-independent growth assays\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic mTORC2 inhibition with biochemical dissection of AKT phosphorylation sites\",\n      \"pmids\": [\"24615340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DISC1 inhibits NRG1-induced ErbB4 activation in mature cortical interneurons; this inhibition is mediated by competitive inhibition of ErbB4 binding to PSD95 by DISC1. Cell-type-specific gene modulation shows that interneuronal DISC1 affects NRG1-ErbB4-mediated phenotypes in fast-spiking interneuron-pyramidal neuron circuits.\",\n      \"method\": \"Cell-type-specific viral gene modulation in vitro and in vivo, mutant DISC1 mouse model, ErbB4 phosphorylation assays, PSD95-ErbB4 co-immunoprecipitation, electrophysiology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic competition for PSD95 binding validated by biochemistry and confirmed in mouse model with electrophysiological readouts\",\n      \"pmids\": [\"26656849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"NRG1 and HGF provide resistance to MEK inhibitor (trametinib) treatment in metastatic uveal melanoma; mechanistically, trametinib enhances NRG1 responsiveness, and NRG1 sustains AKT signaling through ERBB3 to bypass MEK inhibition. Inhibition of ERBB3 or AKT overcomes NRG1-provided resistance; stromal fibroblasts producing NRG1 confer resistance via paracrine signaling.\",\n      \"method\": \"Growth factor screening, NRG1 stimulation with MEK inhibitor, AKT/ERBB3 phosphorylation assays, ERBB3 inhibition, conditioned medium experiments, xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established with multiple pharmacological tools in vitro and in vivo\",\n      \"pmids\": [\"25952648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD74-NRG1 fusion gene expression promotes phosphorylation of ErbB2/3, activates PI3K/AKT/NF-κB signaling, and enhances expression of secreted IGF2 in an NF-κB-dependent manner; IGF2 activates IGF1R to create an autocrine/paracrine circuit that promotes cancer stem cell properties and tumor initiation. Inhibition of ErbB2, PI3K, NF-κB, or IGF2 suppresses tumor sphere formation.\",\n      \"method\": \"ErbB2/3 phosphorylation assays, NF-κB reporter, IGF2 ELISA, IGF1R phosphorylation, limiting dilution xenograft assay, pharmacological inhibition of pathway components\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic signaling pathway traced through NF-κB to IGF2 autocrine loop with multiple inhibitors and in vivo xenograft validation\",\n      \"pmids\": [\"26837769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A RET-ER81-NRG1 signaling pathway in mechanosensory neurons is required for Pacinian corpuscle formation; Ret maintains Er81 expression, Er81 (but not myelination-related NRG1 isoforms) controls specific Nrg1 isoform expression needed for axon-nonmyelinating Schwann cell communication. Ablating Nrg1 in mechanosensory neurons eliminates Pacinian corpuscles, and distinct NRG1 isoforms are used to interact with myelinating vs. non-myelinating Schwann cells.\",\n      \"method\": \"Er81 conditional knockout, Nrg1 conditional knockout in sensory neurons, histological analysis of Pacinian corpuscles, isoform-specific RT-PCR\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout genetics establishing epistatic pathway with isoform-specific molecular mechanism\",\n      \"pmids\": [\"27707970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Spironolactone inhibits ErbB4 receptor phosphorylation and acts as an antagonist of NRG1-ErbB4 signaling; transgenic mice overexpressing Nrg1 type III display cortical ErbB4 hyperphosphorylation, and spironolactone treatment reverses this hyperphosphorylation. Spironolactone treatment ameliorates schizophrenia-relevant behavioral endophenotypes (sensorimotor gating, hyperactivity, working memory) in Nrg1 type III transgenic mice and increases spontaneous inhibitory postsynaptic currents in cortical slices.\",\n      \"method\": \"Cell-based split-TEV assay screening, ErbB4 phosphorylation biochemical assays, NRG1 type III transgenic mice, behavioral tests, cortical slice electrophysiology\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological mechanism validated in transgenic mouse model with electrophysiological and behavioral readouts\",\n      \"pmids\": [\"28743784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NRG1-Fc (a fusion protein of NRG1 EGF-like domain with IgG1 Fc domain) triggers potent AKT activation in the liver, lowers blood glucose, improves insulin sensitivity, and suppresses food intake in obese mice. NRG1-Fc acts as a secretagogue for FGF21 (largely dispensable for its metabolic effects) and directly targets hypothalamic POMC neurons to promote membrane depolarization and increase firing rate, establishing dual hepatic and central mechanisms.\",\n      \"method\": \"NRG1-Fc injection in obese mice, AKT phosphorylation in liver, electrophysiology of POMC neurons, FGF21 knockout mice, glucose tolerance tests\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dual central and hepatic mechanisms established with electrophysiology and genetic FGF21 knockout controls\",\n      \"pmids\": [\"29515030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SLC3A2-NRG1 fusion protein contains the SLC3A2 transmembrane domain and NRG1 EGF-like domain; it binds ERBB3 and ERBB4, promotes ERBB2-ERBB3 heterocomplex formation, and activates PI3K-AKT and MAPK signaling to drive colony formation and tumor growth. Dual inhibition of both ERBB2 and ERBB3 (but not either alone) is required to effectively block downstream signaling from this fusion.\",\n      \"method\": \"Ligand-receptor binding assays, ERBB2/3 co-immunoprecipitation, siRNA knockdown of ERBB2/ERBB3, pharmacological inhibition (pertuzumab, lumretuzumab, afatinib), xenograft models\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — binding assays confirming receptor engagement, dual knockdown establishing signaling requirement, validated in vivo\",\n      \"pmids\": [\"29959202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NRG1 fusions (including CD74-NRG1, ATP1B1-NRG1, SDC4-NRG1) encode chimeric ligands that activate ERBB receptor tyrosine kinase family signaling by presenting the NRG1 EGF-like domain on the cell surface, leading to HER3-HER2 heterodimerization and downstream PI3K-AKT and MAPK pathway activation, driving oncogenic growth in solid tumors.\",\n      \"method\": \"RNA sequencing for fusion detection, ERBB2/3 phosphorylation assays in fusion-positive cell lines, xenograft tumor models, bispecific antibody (zenocutuzumab) blocking of HER3-NRG1 interaction\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanism validated across multiple fusion partners with in vitro signaling assays and in vivo xenograft models\",\n      \"pmids\": [\"35135829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NRG1 ubiquitination is increased in stress-susceptible mice; the E3 ubiquitin ligase Nedd4l directly targets NRG1 for ubiquitin-mediated degradation in the medial prefrontal cortex (mPFC). Overexpression of Nedd4l decreases NRG1 protein levels and causes vulnerability to stress-induced depression-like behaviors, while downregulation of Nedd4l in mPFC rescues stress vulnerability. NRG1 overexpression attenuates depression-like behaviors in CSDS model.\",\n      \"method\": \"Ubiquitination assays, Nedd4l overexpression/knockdown via viral vectors, NRG1 protein quantification, CSDS behavioral model, RNA sequencing\",\n      \"journal\": \"Translational psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — E3 ligase-substrate relationship established with ubiquitination assay and bidirectional in vivo manipulation\",\n      \"pmids\": [\"32703967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NRG1/ERBB4 autocrine signaling in cardiac endothelial cells (ECs) plays a role in modulating hypertrophic and fibrotic responses during early cardiac remodeling; EC-specific ERBB4 knockout attenuates myocardial hypertrophy and fibrosis 8 weeks after transverse aortic constriction and reduces fibrosis after angiotensin II treatment, though these differences normalize over time. RNA sequencing shows NRG1 controls expression of hypertrophic and fibrotic pathway genes in ECs.\",\n      \"method\": \"EC-specific Erbb4 conditional knockout, transverse aortic constriction model, angiotensin II treatment, cardiac histology, RNA sequencing of cultured ECs\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific knockout with defined cardiac phenotype and transcriptomic mechanism\",\n      \"pmids\": [\"32618511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Biallelic variants in ERBB3 and ERBB2 (NRG1 receptors) cause a developmental disorder with HSCR, CIPO, peripheral neuropathy, and arthrogryposis; gut histology reveals aganglionosis and smooth muscle abnormalities. Mouse single-cell RNA sequencing and conditional ErbB3-deficient mouse show a primary role for ERBB3 in enteric progenitors. Functional analyses reveal the identified variants cause decreased expression or altered phosphorylation of the mutant receptors.\",\n      \"method\": \"Trio-exome sequencing, ErbB3 conditional mouse knockout, single-cell RNA sequencing, RT-qPCR and immunoblot of patient-derived fibroblasts and transfected cells\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetics validated by mouse conditional knockout with single-cell transcriptomic characterization\",\n      \"pmids\": [\"33497358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"VAMP2-NRG1 and SLC3A2-NRG1 fusion proteins are membrane-bound and display the NRG1 EGF-like domain extracellularly; KRAS mutation increases ADAM17 metalloprotease activity, which cleaves/sheds NRG1 from the SLC3A2-NRG1 fusion protein via KRAS-MEK-ERK signaling, enhancing ERBB2-ERBB3 phosphorylation and downstream PI3K/AKT/mTOR signaling even under oncogenic KRAS. MEK1/2 and ADAM17 inhibitors synergistically induce apoptosis.\",\n      \"method\": \"ADAM17 activity assays, MEK inhibitors, NRG1 shedding measurement, ERBB2/3 phosphorylation, xenograft and lung orthotopic tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ADAM17-mediated NRG1 shedding mechanism established with enzymatic assays and pharmacological inhibition in multiple models\",\n      \"pmids\": [\"34743207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Stromal cancer-associated fibroblasts (CAFs) express NRG1 and signal paracrinally to luminal breast cancer cells to phosphorylate HER3 (ERBB3) and activate AKT and ERK1/2; simultaneously, NRG1 drives a HER3-independent pro-fibrotic and migratory phenotype in CAFs themselves. HAS2 (Hyaluronan Synthase 2) is identified as a targetable molecule strongly correlated with NRG1 in CAFs.\",\n      \"method\": \"CAF-conditioned medium, NRG1 neutralizing antibodies, siRNA knockdown, HER3 phosphorylation assays, CAF migration/invasion assays, transcriptomic profiling\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional NRG1 signaling (paracrine to cancer cells, autocrine in CAFs) demonstrated with multiple functional assays\",\n      \"pmids\": [\"33692466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NRG1/ErbB signaling controls dialogue between foxd3-positive neural crest-derived cells (NCdC) and macrophages during zebrafish fin regeneration; NCdC regulate macrophage recruitment and polarization through the NRG1/ErbB pathway, which is required for blastema formation. Chemical inhibition and transcriptomic analysis establish NRG1/ErbB pathway as the molecular link between NCdC and macrophage behavior during regeneration.\",\n      \"method\": \"Triple transgenic zebrafish live imaging, genetic NCdC depletion, NRG1/ErbB chemical inhibition, single-cell RNA sequencing, transcriptomic analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological manipulation with scRNA-seq establishing pathway in defined cellular context\",\n      \"pmids\": [\"34732706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NFKB2 directly binds the promoter region of NRG1 and inhibits NRG1 transcription; in IL-1β-stimulated nucleus pulposus cells, NFKB2 is upregulated leading to NRG1 downregulation. NRG1 activates ErbB2/3 to sustain PI3K-AKT signaling protecting against degenerative changes; NFKB2 silencing attenuates degeneration via NRG1, and this effect is reversed by NRG1 silencing.\",\n      \"method\": \"ChIP for NFKB2 binding to NRG1 promoter, luciferase reporter assays, siRNA knockdown, ErbB2/3 and AKT phosphorylation assays, cell viability and apoptosis assays\",\n      \"journal\": \"Mechanisms of ageing and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay establish direct transcriptional repression, validated by epistasis with NRG1 knockdown\",\n      \"pmids\": [\"34023356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Nrg1 regulates cardiomyocyte-oriented cell division and trabeculae formation through endocardial Nrg1-to-myocardial ErbB2 signaling and phospho-ERK activation; early loss of Nrg1 reduces cardiomyocyte Pard3 and Crumbs2 polarity proteins, alters cytoskeletal actin gene expression, and shifts cardiomyocyte division orientation. Nrg1 is required for an EMT-like process in cardiomyocytes including migration, adhesion, and G2/M cell cycle progression. Ectopic Nrg1 overexpression causes S-phase arrest and prolonged trabeculation. Yap1 nuclear-cytoplasmic distribution is influenced by Nrg1 via pERK.\",\n      \"method\": \"Cardiac-specific Nrg1 knockout and overexpression, confocal imaging, transcriptomics, pERK and Pard3/Crumbs2 protein analysis, cell division orientation measurement, Yap1 nuclear-cytoplasmic localization imaging\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (KO and OE) with multiple orthogonal biochemical and imaging readouts establishing Nrg1-ErbB2-pErk-Yap1 axis\",\n      \"pmids\": [\"37846569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In pancreatic ductal adenocarcinoma, cancer-associated fibroblasts (CAFs) secrete NRG1 which activates ERBB2 and ERBB3 on cancer cells as a KRAS*-independent survival mechanism. Genetic extinction or pharmacological inhibition of KRAS* upregulates ERBB2 and ERBB3 expression in cancer cells, prompting utilization of CAF-derived NRG1. Genetic depletion or pharmacological inhibition of ERBB2/3 or NRG1 abolishes KRAS bypass and synergizes with KRASG12D inhibitors.\",\n      \"method\": \"KRAS* conditional extinction, NRG1 genetic depletion in CAFs, ERBB2/3 pharmacological inhibition, KRASG12D inhibitor combination in mouse and human PDAC models\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — causal genetic and pharmacological manipulation in multiple models establishing CAF-NRG1-ERBB2/3 as resistance mechanism\",\n      \"pmids\": [\"37775182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NRG1 fusions activate downstream signaling not only through HER2-HER3 heterodimers but also through HER4 independently of other HER family members, and through EGFR-HER3 signaling. Inhibition of HER4 and EGFR in addition to HER2/HER3 is necessary to effectively inhibit NRG1 fusion-driven tumor cell growth; pan-HER inhibition is more effective than selective targeting of HER2-HER3 or HER3 alone.\",\n      \"method\": \"Ba/F3 engineered cell lines with defined HER family member combinations, ERBB phosphorylation assays, cetuximab/trastuzumab/pertuzumab combination studies, in vitro and in vivo tumor growth assays with pan-HER TKIs\",\n      \"journal\": \"Journal of thoracic oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — engineered cell systems with defined receptor compositions establishing HER4/EGFR contributions, validated in vivo\",\n      \"pmids\": [\"37678511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Adipocyte precursors secrete NRG1 which activates ERBB3 (HER3) signaling on urothelial and lung cancer cells in a paracrine manner, conferring resistance to FGFR inhibition (erdafitinib). NRG1 expression is significantly higher in adipocyte precursors than terminally differentiated adipocytes. NRG1 knockdown in adipocyte precursors abrogates resistance; pharmacological inhibition of the NRG1/HER3 axis with pertuzumab reverses erdafitinib resistance in vivo.\",\n      \"method\": \"Co-culture of adipocyte precursors and cancer cells, NRG1 knockdown in adipocyte precursors, ERBB3 phosphorylation assays, pertuzumab treatment, xenograft survival experiments, scRNA-seq\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — paracrine mechanism with knockdown and antibody blocking, validated in xenograft in vivo\",\n      \"pmids\": [\"38175774\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NRG1 is a secreted/membrane-anchored EGF-like growth factor that signals primarily by binding ErbB3 (HER3) and ErbB4 (HER4) receptors, which heterodimerize with ErbB2 (HER2) — stabilized by ErbB2 acting as a pan-ErbB auxiliary subunit that decelerates ligand dissociation and amplifies signaling — to activate downstream PI3K-AKT, MAPK/ERK, and SAPK/JNK pathways; NRG1 produces multiple functionally distinct isoforms through alternative promoter usage and splicing (Types I–VI), with isoform-specific roles in Schwann cell myelination (Type III), cranial ganglia and cardiac trabeculation (Type I), and activity-dependent synaptic regulation (Types I/IV), the latter controlled by CREB-dependent transcription; NRG1 protein stability is regulated by the E3 ubiquitin ligase Nedd4l-mediated ubiquitination and degradation, and ErbB2 receptor stability is maintained by the adaptor Erbin via its PDZ domain; NRG1 plays essential roles in cardiac trabeculation (endocardial-to-myocardial paracrine signaling through ErbB2-pERK-Yap1), cardiomyocyte proliferation and regeneration (via ErbB4, selectively in mononucleated cells), oligodendrocyte proliferation/survival, peripheral myelination, mammary lactation (basal-cell p63-driven transcription of NRG1 activating luminal ERBB4/STAT5A), hypothalamic POMC neuron depolarization, and modulation of NMDA receptor function via ErbB4-PSD95 interactions in cortical interneurons; oncogenic NRG1 gene fusions present the EGF-like domain on the cell surface, constitutively activating HER2-HER3 (and HER4/EGFR) heterodimers and downstream PI3K-AKT/MAPK signaling, with CAF-derived paracrine NRG1 also serving as a resistance mechanism to targeted therapies including KRAS and FGFR inhibitors.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NRG1 (neuregulin-1) is a growth and differentiation factor that signals through ERBB receptor tyrosine kinases to regulate neural development, myelination, cardiac morphogenesis, mammary gland maturation, and metabolic homeostasis. NRG1 binds directly to ERBB3 or ERBB4, promoting heterodimerization with ERBB2, which acts as a co-receptor that decelerates ligand dissociation and amplifies downstream PI3K-AKT, RAS-ERK/MAPK, and mTORC2 signaling [PMID:8617201, PMID:7731691, PMID:24615340]; NRG1 protein levels are post-translationally regulated by Nedd4l-mediated ubiquitination and ADAM17-dependent ectodomain shedding [PMID:32703967, PMID:34743207], while isoform-specific transcription is controlled by neuronal activity through CRE/CREB elements and by p63 in mammary basal cells [PMID:21653853, PMID:24412575]. In cancer, oncogenic NRG1 gene fusions constitutively present the EGF-like domain to activate ERBB2-ERBB3 signaling and downstream PI3K-AKT/NF-κB pathways, and paracrine NRG1 from cancer-associated fibroblasts confers resistance to KRAS, MEK, and FGFR inhibitors by sustaining ERBB3-dependent AKT activation [PMID:26134228, PMID:37775182, PMID:38175774].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Establishing that NRG1 (NDF) directly engages Neu/HER2 with high affinity and activates PI3K revealed the receptor mechanism, but raised the question of whether HER2 was the direct receptor or a co-receptor requiring additional binding partners.\",\n      \"evidence\": \"Radiolabeled NDF cross-linking, direct binding assays, and PI3K co-IP in mammary tumor cells vs. ovarian cells\",\n      \"pmids\": [\"8096177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific co-factor identity unknown\", \"ERBB3/ERBB4 not yet identified as direct receptors\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of ERBB3 as the direct high-affinity NRG1 receptor and delineation of isoform-specific binding (beta > alpha) resolved the question of direct receptor identity and explained differential potency of NRG1 variants.\",\n      \"evidence\": \"Radioligand binding and receptor profiling in keratinocytes lacking ERBB4; Shc/Grb2/PI3K co-IP in breast cancer cells\",\n      \"pmids\": [\"7731691\", \"9019162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ERBB4 contribution to NRG1 signaling not yet characterized in these systems\", \"Structural basis for beta vs. alpha affinity difference unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstrating that ERBB2 functions as a shared co-receptor that decelerates ligand dissociation and potentiates MAPK/SAPK signaling established the heterodimerization model central to NRG1 signal transduction, while NRG1 was simultaneously shown to act as a mitogen and survival factor for oligodendrocyte progenitors.\",\n      \"evidence\": \"ER-trapped anti-ERBB2 antibody, kinetic binding assays, kinase assays; oligodendrocyte proliferation/survival assays with anti-NRG1 blocking antibodies\",\n      \"pmids\": [\"8617201\", \"8780647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of NRG1-ERBB heterodimer not resolved\", \"In vivo myelination role not yet genetically tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"NRG1 was shown to promote cortical neuron migration along radial glia via ERBB2, and comprehensive downstream pathway mapping in prostate cancer cells revealed NRG1 activates PI3K, ERK, p38, and JNK but not PLCγ or STATs through ERBB3-ERBB2 crosstalk; an autocrine NRG1 loop was identified in Schwann cells.\",\n      \"evidence\": \"In vivo cortical slice migration assays with ERBB2 loss-of-function; pathway-specific kinase assays; Schwann cell NRG1 secretion ELISA and antibody neutralization\",\n      \"pmids\": [\"9342043\", \"9400997\", \"9417836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform-specific contributions to migration vs. myelination unresolved\", \"In vivo Schwann cell autocrine loop significance not genetically confirmed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic evidence that Erbin stabilizes ERBB2 protein and that loss of this stabilization causes peripheral nerve hypomyelination established that NRG1/ERBB2 signaling is essential for Schwann cell myelination in vivo.\",\n      \"evidence\": \"Erbin knockout and PDZ-deletion knock-in mice with nerve morphology and conduction velocity analysis\",\n      \"pmids\": [\"19458253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Erbin modulates NRG1 signaling beyond myelination unknown\", \"Downstream transcriptional targets in myelinating Schwann cells not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that LH induces NRG1 type III via ERK/C/EBPβ in granulosa cells, where NRG1 selectively activates AKT through ERBB3/ERBB2 and synergizes with amphiregulin, extended NRG1 function to reproductive physiology.\",\n      \"evidence\": \"Granulosa cell culture with pathway inhibitors, receptor phosphorylation assays, oocyte maturation competence\",\n      \"pmids\": [\"21047912\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NRG1 is essential for ovulation in vivo not genetically tested\", \"Mechanism of NRG1-AREG synergy at the receptor level unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showing that neuronal activity selectively upregulates type I and IV NRG1 isoforms through a CRE/CREB-dependent mechanism revealed how NRG1 expression is dynamically regulated in the nervous system.\",\n      \"evidence\": \"Activity manipulation, quantitative RT-PCR, CRE mutagenesis, CREB binding assays in neurons\",\n      \"pmids\": [\"21653853\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether activity-dependent NRG1 regulation controls synaptic plasticity in vivo not demonstrated\", \"Epigenetic regulation of other isoform promoters unexplored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Three discoveries expanded the mechanistic picture: p63 was identified as a direct transcriptional activator of Nrg1 in mammary basal cells driving ERBB4/STAT5A-dependent lactogenesis; NRG1 was shown to trigger TrkB-ErbB4 complex formation and BDNF release coupling to NR2B NMDA receptor phosphorylation; and HRG/NRG1-mediated transformation was found to require mTORC2/Rictor for full AKT activation.\",\n      \"evidence\": \"Conditional p63 KO with ChIP; TrkB-ErbB4 proximity ligation and co-IP with genetic/pharmacological inhibition; Rictor siRNA with anchorage-independent growth\",\n      \"pmids\": [\"24412575\", \"25052836\", \"24615340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT5A is the sole effector of NRG1 in luminal progenitors not tested\", \"Structural basis for TrkB-ErbB4 interaction unknown\", \"mTORC2 contribution in non-transformed NRG1 signaling contexts unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Functional characterization of NRG1 gene fusions (VAMP2-NRG1) as constitutive ERBB2/ERBB3 activators, together with discovery that NRG1/ERBB3-mediated AKT activation confers resistance to MEK inhibition, established NRG1 as both an oncogenic driver and a therapy resistance factor.\",\n      \"evidence\": \"ERBB2/3/AKT/ERK phosphorylation in fusion-expressing cells; soft agar growth; MEK inhibitor resistance screens with ERBB3 antibody rescue in xenografts\",\n      \"pmids\": [\"26134228\", \"25952648\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Prevalence and partner diversity of NRG1 fusions across cancer types incompletely catalogued\", \"Whether NRG1-mediated resistance operates in all MEK-inhibitor-treated tumors unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A RET-ER81-NRG1 transcriptional cascade in mechanosensory neurons was shown to control Pacinian corpuscle development through specific NRG1 isoforms distinct from those governing myelination, while CD74-NRG1 fusion was found to activate an NF-κB/IGF2 autocrine loop driving cancer stemness.\",\n      \"evidence\": \"Conditional ER81 and Nrg1 KO mice with corpuscle morphology; NF-κB reporter, IGF2/IGF1R assays, limiting-dilution xenograft\",\n      \"pmids\": [\"27707970\", \"26837769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER81 regulates NRG1 in other sensory neuron subtypes unknown\", \"Generality of the NF-κB/IGF2 loop across NRG1 fusion types not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"SLC3A2-NRG1 fusion was shown to bind ERBB3 and ERBB4 and require dual ERBB2+ERBB3 inhibition for full signaling blockade, while NRG1-Fc was demonstrated to activate hepatic AKT to suppress gluconeogenesis and directly depolarize hypothalamic POMC neurons, expanding NRG1 into metabolic regulation.\",\n      \"evidence\": \"Ligand-receptor binding, siRNA knockdown of receptors, xenograft models; liver AKT phosphorylation, POMC electrophysiology, FGF21 KO mice\",\n      \"pmids\": [\"29959202\", \"29515030\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous NRG1 regulates glucose homeostasis physiologically not established\", \"Structural basis for why dual HER2+HER3 inhibition is required not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Nedd4l was identified as the E3 ubiquitin ligase targeting NRG1 for proteasomal degradation, with stress-induced Nedd4l upregulation reducing NRG1 protein in the medial prefrontal cortex, linking NRG1 post-translational regulation to depression-like behavior.\",\n      \"evidence\": \"Ubiquitination assays, viral Nedd4l overexpression/knockdown in mPFC, chronic social defeat stress model\",\n      \"pmids\": [\"32703967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Nedd4l-NRG1 axis operates in peripheral tissues unknown\", \"Specific lysine residues on NRG1 targeted by Nedd4l not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Multiple studies converged to show that: oncogenic KRAS enhances ADAM17-mediated NRG1 shedding from fusion proteins to activate ERBB2/3/PI3K; NRG1 signals through ERBB3 in enteric progenitors (with human ERBB3 loss-of-function causing aganglionosis); endothelial NRG1/ERBB4 autocrine signaling modulates cardiac hypertrophy; and CAF-derived NRG1 confers KRAS-independent survival to pancreatic cancer cells.\",\n      \"evidence\": \"ADAM17/MEK inhibitor experiments in xenografts; conditional ErbB3-KO mice with patient exome sequencing; EC-specific ErbB4-KO with cardiac stress models; KRAS extinction models with CAF co-culture\",\n      \"pmids\": [\"34743207\", \"33497358\", \"32618511\", \"37775182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ADAM17 cleavage site on NRG1 fusion proteins not precisely mapped\", \"Whether ERBB3 mutations cause Hirschsprung disease as a Mendelian entity requires larger cohorts\", \"Endothelial ERBB4 downstream effectors in fibrosis incompletely defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Endocardial NRG1 was shown to control cardiomyocyte oriented division, trabeculation, and polarity protein expression through ErbB2-ERK-Yap1 signaling, while NRG1 fusions were demonstrated to also signal through HER4 and EGFR-HER3 independently of HER2, expanding the receptor repertoire beyond the canonical HER2-HER3 model.\",\n      \"evidence\": \"Cardiac-specific Nrg1 KO/overexpression with confocal imaging and transcriptomics; Ba/F3 engineered cells expressing defined HER combinations with NRG1 fusions\",\n      \"pmids\": [\"37846569\", \"37678511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Yap1 nuclear-cytoplasmic shuttling integrates with NRG1-ERK signaling mechanistically unclear\", \"Relative clinical importance of HER4/EGFR vs. HER2/HER3 in NRG1 fusion cancers not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Adipocyte precursor-derived NRG1 was identified as the paracrine mediator of resistance to FGFR inhibitors via HER3, demonstrating that CAF-NRG1-ERBB3 bypass signaling generalizes across multiple targeted therapy contexts.\",\n      \"evidence\": \"NRG1 knockdown in adipocyte precursors, pertuzumab reversal, xenograft survival, scRNA-seq\",\n      \"pmids\": [\"38175774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NRG1-mediated resistance extends to other RTK-targeted therapies beyond KRAS/MEK/FGFR not systematically tested\", \"Mechanism by which CAFs upregulate NRG1 expression unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for NRG1-ERBB heterodimer selectivity; the full repertoire of NRG1 isoform-specific functions in vivo; the mechanism by which NRG1 signals independently of HER3 in CAFs; and whether endogenous NRG1 physiologically regulates metabolism.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of NRG1 EGF-like domain bound to ERBB3/ERBB4 heterodimer\", \"Isoform-specific knockout models for most NRG1 types lacking\", \"HER3-independent NRG1 signaling in fibroblasts not mechanistically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 3, 13, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 6, 10, 17, 21, 30, 33]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [13, 15, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 7, 13, 14, 15, 23]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 8, 12, 18, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 16, 21, 24, 25, 30, 32]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [9, 11, 19, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ERBB2\",\n      \"ERBB3\",\n      \"ERBB4\",\n      \"NEDD4L\",\n      \"ADAM17\",\n      \"DISC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"NRG1 encodes a family of alternatively spliced EGF-like growth factors that signal primarily through ErbB3 (HER3) and ErbB4 (HER4) receptors, which heterodimerize with ErbB2 (HER2) to activate PI3K-AKT, MAPK/ERK, and SAPK/JNK cascades, governing cell proliferation, survival, differentiation, and myelination across neural, cardiac, epithelial, and metabolic tissues [PMID:1350381, PMID:7514177, PMID:8617201, PMID:9019162]. Distinct NRG1 isoforms (Types I–VI) generated by alternative promoter usage and splicing serve non-redundant developmental functions: Type III NRG1 drives Schwann cell development and peripheral myelination, Type I is required for cranial ganglia formation and cardiac trabeculation—where endocardial NRG1 activates myocardial ErbB2–pERK–Yap1 signaling to orient cardiomyocyte division—and activity-dependent Type I/IV expression is controlled by CREB-dependent transcription in neurons [PMID:9342050, PMID:37846569, PMID:21653853]. NRG1–ErbB4 signaling modulates NMDA receptor function via ErbB4–PSD95 interactions in cortical interneurons, and NRG1 hypomorphic mice exhibit reduced NMDA receptors and schizophrenia-relevant behavioral phenotypes partially reversible by clozapine, establishing NRG1 as a schizophrenia susceptibility gene [PMID:12145742, PMID:16767099]. Oncogenic NRG1 gene fusions constitutively present the EGF-like domain at the cell surface to activate HER2–HER3 (and HER4/EGFR) heterodimers, while cancer-associated fibroblast-derived paracrine NRG1 confers resistance to KRAS, MEK, and FGFR inhibitors through sustained ERBB3–AKT signaling [PMID:35135829, PMID:37775182, PMID:38175774].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of NRG1 as the activating ligand of the ErbB2 receptor tyrosine kinase resolved the long-standing question of what physiological signal triggers p185erbB2 phosphorylation.\",\n      \"evidence\": \"Protein purification from conditioned medium with Scatchard binding and chemical cross-linking in two independent studies\",\n      \"pmids\": [\"1350381\", \"1348215\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct receptor (ErbB3/ErbB4) had not yet been identified as the primary binding partner\", \"Downstream signaling pathways not yet mapped\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Reconstitution of the ErbB2–ErbB3 heterodimer as the high-affinity NRG1 receptor established that ErbB2 is not the direct ligand-binding subunit but rather a co-receptor that amplifies signaling through transphosphorylation, while isoform diversity (GGF/heregulin/SMDF) was shown to arise from alternative splicing of a single gene.\",\n      \"evidence\": \"ErbB2/ErbB3 co-transfection with Scatchard analysis, cross-linking, kinase-dead mutagenesis establishing transphosphorylation directionality; cDNA cloning of GGF isoforms\",\n      \"pmids\": [\"7514177\", \"8096067\", \"7556068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of ErbB4 vs ErbB3 in different tissues unclear\", \"Structural basis of heterodimer formation unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that ErbB2 functions as a pan-ErbB auxiliary subunit by decelerating ligand dissociation—and that NRG1 drives oligodendrocyte proliferation/survival and radial glial maintenance—broadened NRG1's role from a receptor activator to a pleiotropic neural growth factor.\",\n      \"evidence\": \"ErbB2 overexpression/surface-depletion with kinetic binding analysis; oligodendrocyte culture with antibody blocking and ErbB receptor phosphorylation; ErbB2 knockout and cortical development analysis in mice\",\n      \"pmids\": [\"8617201\", \"8780647\", \"9342043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which NRG1 controls radial glial vs neuronal targets not separated at isoform level\", \"In vivo relevance of ErbB2 kinetic modulation not yet demonstrated genetically\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Isoform-specific gene targeting revealed that Type I and Type III NRG1 have non-redundant functions—Type I in cranial ganglia and cardiac trabeculation, Type III in Schwann cell development—demonstrating that alternative splicing generates functionally distinct signaling molecules.\",\n      \"evidence\": \"Targeted isoform-specific mutations in mice with histological analysis of distinct developmental phenotypes\",\n      \"pmids\": [\"9342050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Type IV, V, VI isoform functions not yet characterized\", \"Molecular basis for isoform-specific receptor engagement unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linkage and association studies identified NRG1 as a schizophrenia susceptibility locus, and NRG1 hypomorphic mice showed reduced NMDA receptors and clozapine-reversible behavioral phenotypes, connecting NRG1 to synaptic glutamate signaling.\",\n      \"evidence\": \"Genome-wide linkage scan, haplotype association, NRG1 hypomorph mice with NMDA receptor quantification and pharmacological rescue\",\n      \"pmids\": [\"12145742\", \"12478479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal variants within the NRG1 locus not identified\", \"Whether NRG1-ErbB4 directly regulates NMDA receptor trafficking or function was unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Postmortem studies established that NRG1-induced ErbB4 hyperactivation and enhanced ErbB4–PSD95 interaction suppress NMDA receptor activation in schizophrenia prefrontal cortex, providing a molecular mechanism for NMDA hypofunction; disease-associated SNPs were shown to regulate isoform-specific expression including the novel Type IV isoform.\",\n      \"evidence\": \"Postmortem tissue NRG1 stimulation with ErbB4 phosphorylation and PSD95 co-IP; quantitative RT-PCR genotype-expression correlation in hippocampus\",\n      \"pmids\": [\"16767099\", \"16618933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PSD95–ErbB4 interaction is the primary mechanism of NRG1-induced NMDA suppression in vivo\", \"Functional validation of SNP-altered transcription factor binding sites lacking\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"NRG1–ErbB4 signaling was shown to drive mononucleated cardiomyocyte proliferation and promote myocardial regeneration after infarction, while Erbin was identified as a PDZ-domain adaptor required for ErbB2 stability and NRG1-dependent peripheral myelination.\",\n      \"evidence\": \"ErbB4 genetic knockout/overexpression with NRG1 injection and lineage tracing in adult mice; Erbin knockout and PDZ-deleted knockin mice with nerve histology and ErbB2 stability assays\",\n      \"pmids\": [\"19632177\", \"19458253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why only mononucleated cardiomyocytes respond to NRG1 is mechanistically unexplained\", \"Whether Erbin functions similarly in CNS myelination unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Direct transcriptional activation of NRG1 by p63 in mammary basal cells established a basal-to-luminal paracrine axis (NRG1→ERBB4→STAT5A) essential for lactation, revealing cell-type-specific transcriptional control of NRG1 with defined physiological consequences.\",\n      \"evidence\": \"Conditional p63 knockout in adult mammary basal cells, ChIP for p63 at Nrg1 promoter, ERBB4/STAT5A phosphorylation, functional lactation assay\",\n      \"pmids\": [\"24412575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other NRG1 isoforms contribute to mammary development not assessed\", \"Mechanism of STAT5A activation by ERBB4 in this context not fully dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Characterization of NRG1 gene fusions (CD74-, SLC3A2-, ATP1B1-NRG1) revealed that chimeric proteins constitutively present the EGF-like domain on the cell surface to activate HER2–HER3 heterodimers and PI3K-AKT/MAPK signaling; ADAM17-mediated shedding of fusion NRG1 was later shown to be enhanced by KRAS-MEK-ERK signaling.\",\n      \"evidence\": \"RNA sequencing for fusion detection, ERBB2/3 phosphorylation assays, zenocutuzumab blocking, ADAM17 activity assays, xenograft models\",\n      \"pmids\": [\"35135829\", \"29959202\", \"34743207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical efficacy of NRG1 fusion-targeted therapies not established\", \"Structural basis for constitutive activation by different fusion partners not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"NRG1 protein stability was shown to be regulated by Nedd4l-mediated ubiquitination in the prefrontal cortex, linking NRG1 degradation to stress vulnerability and depression-like phenotypes and revealing a post-translational control mechanism.\",\n      \"evidence\": \"Ubiquitination assays, Nedd4l overexpression/knockdown via viral vectors, CSDS behavioral model\",\n      \"pmids\": [\"32703967\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Nedd4l targets specific NRG1 isoforms is unknown\", \"Ubiquitination sites on NRG1 not mapped\", \"Independent replication in a second behavioral paradigm lacking\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CAF-secreted NRG1 was identified as a KRAS*-independent survival mechanism in pancreatic cancer: KRAS extinction upregulates ERBB2/3 expression, enabling NRG1-driven bypass; paracrine NRG1 from adipocyte precursors similarly confers resistance to FGFR inhibitors, establishing NRG1–ERBB3 as a general therapeutic resistance axis.\",\n      \"evidence\": \"KRAS conditional extinction with NRG1 genetic depletion in CAFs, ERBB2/3 inhibition in PDAC models; co-culture with adipocyte precursors, NRG1 knockdown, pertuzumab reversal in xenografts\",\n      \"pmids\": [\"37775182\", \"38175774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NRG1-mediated resistance generalizes across all KRAS-mutant cancers untested\", \"Direct clinical validation of combination strategies pending\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"An endocardial NRG1–myocardial ErbB2–pERK–Yap1 axis was shown to orient cardiomyocyte cell division and regulate polarity proteins (Pard3, Crumbs2) during trabeculation, unifying earlier genetic observations into a coherent morphogenetic signaling cascade.\",\n      \"evidence\": \"Cardiac-specific Nrg1 knockout and overexpression with confocal imaging of division orientation, pERK and polarity protein analysis, Yap1 localization\",\n      \"pmids\": [\"37846569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How pERK regulates Yap1 nuclear-cytoplasmic distribution mechanistically unresolved\", \"Whether Pard3/Crumbs2 are direct or indirect pERK targets unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for isoform-specific receptor selectivity, the full spectrum of NRG1 isoform functions in the adult brain, and the clinical impact of targeting the NRG1–ERBB axis in NRG1 fusion-driven cancers and therapy resistance settings.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of NRG1 isoform-specific receptor complexes\", \"Type V and VI isoform functions remain uncharacterized\", \"Clinical trial results for NRG1 fusion-targeted therapies not yet in primary literature\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 3, 5, 38, 39]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 20, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 18, 38, 43]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 14, 44, 48, 50]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [3, 4, 6, 7, 11, 31, 38, 39]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9, 10, 22, 47]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [8, 17, 20, 32]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [34, 38, 39, 48, 49]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ERBB2\", \"ERBB3\", \"ERBB4\", \"PSD95\", \"NEDD4L\", \"ERBIN\", \"ADAM17\"],\n    \"other_free_text\": []\n  }\n}\n```"}